[go: up one dir, main page]

WO1996014842A1 - Substituted heterocycles as inhibitors of nitric oxide synthase - Google Patents

Substituted heterocycles as inhibitors of nitric oxide synthase Download PDF

Info

Publication number
WO1996014842A1
WO1996014842A1 PCT/US1995/014512 US9514512W WO9614842A1 WO 1996014842 A1 WO1996014842 A1 WO 1996014842A1 US 9514512 W US9514512 W US 9514512W WO 9614842 A1 WO9614842 A1 WO 9614842A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
hydrogen
optionally
group
thiazine
Prior art date
Application number
PCT/US1995/014512
Other languages
French (fr)
Inventor
Shrenik K. Shah
Stephan K. Grant
Malcolm Maccoss
Kothandaraman Shankaran
Hongbo Qi
Ravindra N. Guthikonda
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU41496/96A priority Critical patent/AU4149696A/en
Publication of WO1996014842A1 publication Critical patent/WO1996014842A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/06—1,3-Thiazines; Hydrogenated 1,3-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This application is directed to inhibitors of Nitric oxide synthase, and in particular thiazolines and thiazines.
  • nitric oxide a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological processes is one of the major biological revelations of recent times.
  • This molecule is produced under a variety of physiological and pathological conditions by cells mediating vital biological functions. Examples include endothelial cells lining the blood vessels; nitric oxide derived from these cells relaxes smooth muscle and regulates blood pressure and has significant effects on the function of circulating blood cells such as platelets and neutrophils as well as on smooth muscle, both of tr- blood vessels and also of other organs such as the airways.
  • nitric oxide serves as a neurotransmitter in non- adrenergic non-cholinergic neurons.
  • nitric oxide appears to be produced in small amounts on an intermittent basis in response to various endogenous molecular signals.
  • nitric oxide can be synthesized in much larger amounts on a protracted basis. Its production is induced by exogenous or endogenous inflammatory stimuli, notably endotoxin and cytokines elaborated by cells of the host defense system in response to infectious and inflammatory stimuli. This induced production results in prolonged nitric oxide release which contributes both to host defense processes such as the killing of bacteria and viruses as well as pathology associated with acute and chronic inflammation in a wide variety of diseases.
  • nitric oxide synthases which utilize the amino acid arginine and molecular oxygen as co-substrates has provided an understanding of the biochemistry of this molecule and provides distinct pharmacological targets for the inhibition of the synthesis of this mediator, which should provide significant beneficial effects in a wide variety of diseases.
  • Nitric oxide and L-citrulline are formed from L-arginine via the dioxygenase activity of specific nitric oxide synthases (NOSs) in mammalian cells.
  • NOSs specific nitric oxide synthases
  • L-arginine, ⁇ 2 and NADPH are cosubstrates while FMN, FAD and tetrahydrobiopterin are cofactors.
  • NOSs fall into two distinct classes, constitutive NOS (cNOS) and inducible NOS (iNOS) . Two constitutive NOSs have been identified. They are:
  • a constitutive, Ca ++ /calmoduIin dependent enzyme located in the endothelium (ecNOS or NOS 3), that releases NO in response to receptor or physical stimulation
  • a constitutive, Ca ++ /calmodulin dependent enzyme located in the brain (ncNOS or NOS 1) and elsewhere, that releases
  • the third isoform identified is inducible NOS (iNOS or NOS 2): (iii) a Ca ++ independent enzyme which is induced after activation of vascular smooth muscle, macrophages, endothelial cells, and a large number of other cells by endotoxin and cytokines. Once expressed, this inducible NO synthase produces NO in relatively large amounts for long periods of time.
  • NOS 3 acts as an autocoid mediating a number of physiological responses.
  • Two distinct cDNAs accounting for the activity of NOS 1 and NOS 3 in man have been cloned, one for NOS 1 (Nakane et. al, FEBS Letters, 316, 175-182, 1993) which is present in the brain and a number of peripheral tissues, the other for an enzyme present in endothelium
  • NOS 3 Marsden et. al, FEBS Utters, 307, 287-293, 1992. This latter enzyme is critical for production of NO to maintain vasorelaxation.
  • a second class of enzyme, iNOS or NOS 2 has been cloned from human liver (Geller et. al., PNAS, 90, 3491-5, 1993), and identified in more than a dozen other cells and tissues, including smooth muscle cells, chondrocytes, the kidney and airways.
  • this enzyme is induced upon exposure to cytokines such as gamma interferon (IFN- ⁇ ), interleukin- l ⁇ (IL-l ⁇ ), tumor necrosis factor (TNF- ⁇ ) and LPS (lipopolysaccharide).
  • cytokines such as gamma interferon (IFN- ⁇ ), interleukin- l ⁇ (IL-l ⁇ ), tumor necrosis factor (TNF- ⁇ ) and LPS (lipopolysaccharide).
  • IFN- ⁇ gamma interferon
  • IL-l ⁇ interleukin- l ⁇
  • TNF- ⁇ tumor necrosis factor
  • LPS lipopolysaccharide
  • Endothelium derived relaxation factor has been shown to be produced by NOS 3 (Moncada et. al, Pharmacol. Reviews, 43, 109-142, 1991). Studies with substrate analog inhibitors of NOS have shown a role for NO in regulating blood pressure in animals and blood flow in man, a function attributed to NOS 3. NO has also been shown to be an effector of the cytotoxic effects of activated macrophages (Nathan, FASEB J., 6, 3051-64, 1992) for fighting tumour cells and invading microorganisms (Wright et al., Card. Res., 26 ,48-57, 1992 and Moncada et al, Pharmacological Review, 43, 109-142, 1991).
  • NO generated by NOS 2 has been implicated in the pathogenesis of inflammatory diseases.
  • hypotension induced by LPS or TNF- ⁇ can be reversed by NOS inhibitors and reinitiated by L-arginine (Kilbourn et. al, PNAS, 87, 3629- 32, 1990).
  • Conditions which lead to cytokine-induced hypotension include septic shock, hemodialysis (Beasley and Brenner, Kidney Int., 42, Suppl., 38, S96--S100, 1992) and IL-2 therapy in cancer patients (Hibbs et. al, J. Clin. Invest., 89, 867-77, 1992).
  • NOS 2 is implicated in these responses, and thus the possibility exists that a NOS inhibitor would be effective in ameliorating cytokine-induced hypotension.
  • Recent studies in animal models have suggested a role for NO in the pathogenesis of inflammation and pain and NOS inhibitors have been shown to have beneficial effects on some aspects of the inflammation and tissue changes seen in models of inflammatory bowel disease, (Miller et. al, J.
  • cytokines such as TNF, IL-1 and IL-2
  • cytokine-inducing agents for example 5, 6-dimethylxanthenone acetic acid
  • compounds which inhibit NO synthesis may be of use in reducing the NO concentration in patients suffering from inflammatory conditions in which an excess of NO contributes to the pathophysiology of the condition, for example adult respiratory distress syndrome (ARDS) and myocarditis.
  • ARDS adult respiratory distress syndrome
  • an NO synthase enzyme may be involved in the degeneration of cartilage which takes place in autoimmune and/or inflammatory conditions such as arthritis, rheumatoid arthritis, chronic bowel disease and systemic lupus erythematosis (SLE).
  • a yet further aspect of the present invention provides thiazine and thiazolone derivatives or salts thereof in the manufacture of a medicament for use in cytokine or cytokine-inducing therapy, as an adjuvant to short term l o immunosuppression in transplant therapy, for the treatment of patients suffering from inflammatory conditions in which an excess of NO contributes to the pathophysiology of the condition.
  • nitric oxide synthase mediated diseases and disorders including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation.
  • diseases and disorders include hypotension, septic shock, toxic shock syndrome, hemodialysis, 0 IL-2 therapy such as in in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn, eczema or psoriasis and respiratory conditions such as bronchitis, asthma, oxidant-induced lung injury and acute respiratory distress (ARDS), glomerulonephritis, inflammatory sequelae of viral infections, myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension, retinitis and uveitis, type
  • Compounds of Formula I are also usful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, mulitple sclerosis, Korsakoff s disease, imbecility related to l o cerebral vessel disorder, NO mediated cerebral trauma and related sequelae, ischemic brain edema, sleeping disorders, schizophrenia, depression, pre-menstrual syndrome (PMS), anxiety, drug addiction, pain, migraine, immune complex disease, as immunosupressive agents, acute allograft rejection, infections caused by invasive microorganisms
  • PMS pre-menstrual syndrome
  • n O, 1, 2, 3 or 4
  • X is selected from C2, O, S and NH
  • Rl, R2 and R3 are each independently selected from the group consisting of
  • hetero C5-i ⁇ cycloalkyl wherein the hetero C5-l ⁇ cycloalkyl optionally contains 1 or 2 heteroatoms selected from S, 0 and N,
  • aryl selected from phenyl or naphthyl
  • heteroaryl wherein heteroaryl is selected from the group consisting of:
  • R6 is selected from hydrogen, phenyl, cyclohexyl or Ci-6alkyl, each of (b) to (m) being optionally mono or di- substituted the substituents being independently selected from (l) hydroxy,
  • R7 is selected from hydrogen, phenyl, cyclohexyl or Cl-6alkyl
  • halo selected from F, Cl, Br and I
  • halo selected from F, Cl, Br and I
  • phenyl optionally mono or di-substituted with hydroxy, halo, Ci-4alkyl, or Ci-4alkoxy, (c) -CONR8R9, where R8 and R9 are each independently hydrogen, phenyl, cyclohexyl or Ci-6alkyl, said Cl-6alkyl optionally substituted by
  • halo selected from F, Cl, Br and I
  • n 0, 1, 2, 3 or 4
  • X is selected from O, S and NH
  • Rl, R2 and R3 are each independently selected from the group consisting of
  • hetero C5 or C6 cycloalkyl wherein the hetero C5 or C6 cycloalkyl optionally contains 1 heteroatom selected from S,
  • aryl selected from phenyl or naphthyl
  • heteroaryl wherein heteroaryl is selected from the group consisting of:
  • halo selected from F, Cl, Br and I
  • halo selected from F, Cl, Br and I
  • X is selected from O, S and NH, Rl and R2 are each independently selected from the group consisting of
  • R4 is selected from the group consisting of
  • R5 is selected from the group consisting of
  • any variable e.g. Rl, R2, R3, R4, R5, 6, R7, R8, Ra, Rb, k, n, p etc.
  • any variable e.g. Rl, R2, R3, R4, R5, 6, R7, R8, Ra, Rb, k, n, p etc.
  • compounds of Formula I include those wherein there is a double bond at side a or b such as shown in Ia and lb or tautomeric forms thereof
  • p is 0, 1, or 2 and n is defined as above and wherein the second ring may contain up to three hetero atoms selected from N, O or S
  • p is 0, 1, or 2 and wherein the second ring may contain up to three hetero atoms selected from N, O or S
  • alkyl is defined to include linear, branched, and cyclic structures, with Cl-6alkyl including methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • Ci-6alkoxy is intended to include alkoxy groups of from 1 to 6 carbon atoms of a straight, branched, or cyclic configuration. Examples of lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like.
  • C 1-6 alkylthio is intended to include alkylthio groups of from 1 to 6 carbon atoms of a straight, branched or cyclic configuration.
  • Examples of lower alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc.
  • the propylthio group signifies -SCH2CH2CH3.
  • Heteroaryl includes furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1,2,3-triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,3,4-triazole, 1,2,5-oxadiazole, 1,2,5-thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,4,5-tetrazine, and the like.
  • the compounds of the instant invention are useful for in the treatment of a number of NOS implicated diseases.
  • NOS implicated diseases The implication of these diseases is well documented in the literature.
  • psoriasis see Ruzicka et. al, J. Invest. Derm., 103: 397 (1994) or Kolb-Bachofen et. al, Lancet, 344: 139 (1994) or Bull, et al., J. Invest. Derm., 103:435(1994); with regard to uveitis, see Mandia et.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • l o Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium
  • phosphate 20 phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxy-
  • dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide l o with long chain aliphatic alcohols, for example heptadecaethylene- oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p- hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth
  • compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granule 1- suitable for preparation of an aqueous suspension by the addition of wat provide the active
  • compositions of the invention may also be in the form of an oil-in- water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy beans, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
  • Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • compositions may also be administered in the form of a suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • topical use creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
  • Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the
  • inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day, preferably 2.5 mg to 1 g per patient per day.
  • l o
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an
  • Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
  • NOS activity is measured as the formation of L-[2,3,4,5- 3H]Citrulline from L-[2,3,4,5-3H]Arginine.
  • the incubation buffer 100 30 ⁇ L contained; 100 mM TES, pH 7.5, 5 ⁇ M FAD, 5 ⁇ M FMN, 10 ⁇ M BH4, 0.5 mM NADPH, 0.5 mM DTT, 0.5 mg/mL BSA, 2 mM CaC12, 10 ⁇ g/mL calmodulin (bovine), 1 ⁇ M L-Arg, 0.2 ⁇ Ci L-[2,3,4,5- 3 H]Arg, and the inhibitor in aqueous DMSO (max. 5 %).
  • the reaction is initiated by addition of enzyme.
  • the aminoalkyl halides starting materials are commercially available or they can be prepared by the methods known to those skilled in the art.
  • the amine substrate for the displacement reaction may contain a different leaving group such as a mesylate or a tosylate which are prepared fron the corresponding alcohol using the methods described in March J. Advanced Organic Chemistry, 3rd ed., John Wiley & Sons, New York, p. 444 (1985).
  • the amine is first reacted with an acylating agent such as an alkyl, aryl or acyl isothiocyanate and the resulting thiourea is cyclized upon heating with or without a base 5 catalyst. If an acylisothiocyanate is used (Example 19) a 2- acylaminothiazine product is obtained.
  • Path c of scheme 1 shows a third way for forming the desired ring structures.
  • the aminoalcohol, halide or other l o suitable derivative is reacted with carbon disulfide to form the heterocyclic ring system with a thiocarbonyl group.
  • Methylation and displacement of the resulting methylthio group with ammonia or an amine gives the desired 2-amino substituted heterocycle.
  • the 2-aminothiazoline (and other rings) prepared by methods shown in schemes 1 or 2 can be further modified, for example by acylation (scheme 3).
  • acylation Scheme 3
  • reaction of 2-Amino-5,6-dihydro-4H-l,3- thiazine with an acid chloride or anhydride optionally in the presence of a base gives a 2-acylamino analog.
  • Other acylation procedures as described in March J., Advanced Organic Chemistry, 3rd ed., John Wiley & Sons, New York, (1985) may also be used. If an isocyanate or an isothiocyanate (Example 12) is used for acylation, the product is a urea or a thiourea.
  • ureas or a thioureas can also be prepared by reacting the amino compound with phosgene, thiophosgene, or other carbonyl tranfer reagents such as carbonyldiimidazole or thiocarbonyldiimidazole followed by reaction with another amine (Example 15) .
  • SCHEME 3
  • ⁇ __c. in addition "Ar” signifies an aromatic signal; chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (miHigrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).
  • Mass Spectrum m/e 275,159,145, 142, 129, 117.
  • Mass Spectrum m/e 303, 170, 159, 145, 143, 118, 102(M+1).
  • Mass Spectrum m/e 337, 292, 207, 191, 177, 159.
  • Step B 2-Benzoylamino-4H-3.1-benzothiazine.
  • Step A Na-(t-ButoxycarbonylV5-(2-thiazolinyl)amino-norvaline t- butyl ester.
  • Step B 5-(2-Thiazolin vDamino-norvaline hy drochloride .
  • HC1 gas was passed through 2 mL EtOAc at 0 "C until it was saturated.
  • This solution (2 mL) was added to 54 mg (0.144 mmol) of N 3 - (t-butoxycarbonyl)-5-(2-thiazolinyl)amino-norvaline t-butyl ester (from step A) and the mixture was stirred overnight. A white solid was formed. The mixture was diluted with Et2 ⁇ , the solid was filtered, washed with Et2 ⁇ and dried to isolate 26 mg (71%) of the title compound.
  • Step A 5-CS )-2-Thioxo-3-thia- 1 -aza-bicyclof 3.3 ,0)octane.
  • Step B 5-(SV2-Imino-3-thia-l-aza-bicvclo(3.3.0 octane.
  • Step C 3-Methanesulfonyloxy-2-methyl-butylamine hydrochloride.
  • Step D 2- Amino-cis-5.6-dimethyl-5.6-dihydro-4H- 1 ,3-thiazine. methanesulfonic acid salt
  • the suspension was heated to reflux for 2 h then cooled in ice bath and quenched by sequencially adding 0.48 mL of water, 0.48 mL of 15% NaOH solution and 1.5 mL of water. The mixmre was stirred for 0.5 h to allow the aluminium salts to coagulate. The solution was filtered through Na2S ⁇ 4 and the solid was rinsed with Et2 ⁇ . The combined filtrate was concentrated to yield 0.54 g of the title product as an oil which was used in the next step without purification.
  • Step C 2-Amino-trans-4.5-dimethyl-5.6-dihvdro-4H-L3-thiazine. methane sulfonic acid salt
  • the title compound was prepared from the threo isomer of 3-t-butyloxyamino-2-methyl-l-butanol by the method described in Example 26 steps C and D.
  • Example 30 The title compound was synthesized from erythro 3-t- butyloxyamino-2-methyl-l-butanol (Example 30, step B) according to the procedure of Example 26 steps C and D.
  • Step A trans- l-Amino-2-hydroxymethyl-cyclohexane hvdrochloride
  • the title compound was prepared fron ethyl cyclohexanone- 2-carboxylate by the method described in Example 31 step A.
  • Step B 4-Amino-3-thia-5-aza-trans-bicyclo(4.4.0Vdec-4-ene. methane sulfonic acid salt
  • This compound was prepared from trans- l-amino-2- hydroxymethyl-cyclohexane hydrochloride by the procedure of Example 26 steps C and D.
  • the title compound was prepared from l(R)-2(S)-l-amino- 2-hydroxymethyl-cyclohexane by the method of Example 26 steps C and D.
  • the title compound was prepared from l(S)-2(R)-l-amino- 2-hydroxymethyl-cyclohexane by the method of Example 26 steps C and D.
  • the compounds of Examples 35-38 were synthssized by the method of Example 26 steps C and D starting with the appropriate aminoalcohol.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. Theses diseases and disorders include hypotension, septic shock, toxic shock syndrome, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acute respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis. Compounds of Formula (I) are also useful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Korsakoff's disease, imbecility related to cerebral vessel disorder, ischemic brain edema, sleeping disorders, schizophrenia, depression, PMS, anxiety, drug addiction, pain, migraine, immune complex disease, as immunosupressive agents and for preventing or reversing tolerance to opiates and diazepines.

Description

TITLE OF THE INVENTION
SUBSTITUTED HETEROCYCLES AS INHIBITORS OF NITRIC
OXIDE SYNTHASE
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of Nitric oxide synthase, and in particular thiazolines and thiazines.
Nitric Oxide in Biology.
The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological processes is one of the major biological revelations of recent times. This molecule is produced under a variety of physiological and pathological conditions by cells mediating vital biological functions. Examples include endothelial cells lining the blood vessels; nitric oxide derived from these cells relaxes smooth muscle and regulates blood pressure and has significant effects on the function of circulating blood cells such as platelets and neutrophils as well as on smooth muscle, both of tr- blood vessels and also of other organs such as the airways. In the brain and elsewhere nitric oxide serves as a neurotransmitter in non- adrenergic non-cholinergic neurons. In these instances nitric oxide appears to be produced in small amounts on an intermittent basis in response to various endogenous molecular signals. In the immune system nitric oxide can be synthesized in much larger amounts on a protracted basis. Its production is induced by exogenous or endogenous inflammatory stimuli, notably endotoxin and cytokines elaborated by cells of the host defense system in response to infectious and inflammatory stimuli. This induced production results in prolonged nitric oxide release which contributes both to host defense processes such as the killing of bacteria and viruses as well as pathology associated with acute and chronic inflammation in a wide variety of diseases. The discovery that nitric oxide production is mediated by a unique series of three closely related enzymes, named nitric oxide synthases, which utilize the amino acid arginine and molecular oxygen as co-substrates has provided an understanding of the biochemistry of this molecule and provides distinct pharmacological targets for the inhibition of the synthesis of this mediator, which should provide significant beneficial effects in a wide variety of diseases.
Nitric Oxide Synthases
Nitric oxide and L-citrulline are formed from L-arginine via the dioxygenase activity of specific nitric oxide synthases (NOSs) in mammalian cells. In this reaction, L-arginine, θ2 and NADPH are cosubstrates while FMN, FAD and tetrahydrobiopterin are cofactors. NOSs fall into two distinct classes, constitutive NOS (cNOS) and inducible NOS (iNOS) . Two constitutive NOSs have been identified. They are:
(i) a constitutive, Ca++/calmoduIin dependent enzyme, located in the endothelium (ecNOS or NOS 3), that releases NO in response to receptor or physical stimulation, (ii) a constitutive, Ca++/calmodulin dependent enzyme, located in the brain (ncNOS or NOS 1) and elsewhere, that releases
NO in response to receptor or physical stimulation,
The third isoform identified is inducible NOS (iNOS or NOS 2): (iii) a Ca++ independent enzyme which is induced after activation of vascular smooth muscle, macrophages, endothelial cells, and a large number of other cells by endotoxin and cytokines. Once expressed, this inducible NO synthase produces NO in relatively large amounts for long periods of time.
Spectral studies of both the mouse macrophage iNOS and rat brain ncNOS have shown that these enzymes (which has been classified as P-450-like from their CO-difference spectra) contain a heme moiety. The structural similarity between NOS and the P-450/flavoρrotein complex suggests that the NOS reaction mechanism may be similar to P- 450 hydroxylation and/or peroxidation. This indicates that NOS belongs to a class of flavohemeproteins which contain both heme and flavin binding regions within a single protein in contrast to the multiprotein NADPH oxidase or Cytochrome P-450/NADPH Cyt c reductase complexes.
Distinct Functions of NO Produced by Different Nitric Oxide Synthases. The NO released by the constitutive enzymes (NOS 1 and
NOS 3) acts as an autocoid mediating a number of physiological responses. Two distinct cDNAs accounting for the activity of NOS 1 and NOS 3 in man have been cloned, one for NOS 1 (Nakane et. al, FEBS Letters, 316, 175-182, 1993) which is present in the brain and a number of peripheral tissues, the other for an enzyme present in endothelium
(NOS 3) (Marsden et. al, FEBS Utters, 307, 287-293, 1992). This latter enzyme is critical for production of NO to maintain vasorelaxation. A second class of enzyme, iNOS or NOS 2, has been cloned from human liver (Geller et. al., PNAS, 90, 3491-5, 1993), and identified in more than a dozen other cells and tissues, including smooth muscle cells, chondrocytes, the kidney and airways. As with its counterpart from the murine macrophage, this enzyme is induced upon exposure to cytokines such as gamma interferon (IFN-γ), interleukin- lβ (IL-lβ), tumor necrosis factor (TNF-α) and LPS (lipopolysaccharide). Once induced, iNOS expression continues over a prolonged period of time. The enzyme does not require exogenous calmodulin for activity.
Endothelium derived relaxation factor (EDRF) has been shown to be produced by NOS 3 (Moncada et. al, Pharmacol. Reviews, 43, 109-142, 1991). Studies with substrate analog inhibitors of NOS have shown a role for NO in regulating blood pressure in animals and blood flow in man, a function attributed to NOS 3. NO has also been shown to be an effector of the cytotoxic effects of activated macrophages (Nathan, FASEB J., 6, 3051-64, 1992) for fighting tumour cells and invading microorganisms (Wright et al., Card. Res., 26 ,48-57, 1992 and Moncada et al, Pharmacological Review, 43, 109-142, 1991). It also appears that the adverse effects of excess NO production, in particular pathological vasodilation and tissue damage, may result largely from the effects of NO synthesized by the NOS 2. NO generated by NOS 2 has been implicated in the pathogenesis of inflammatory diseases. In experimental animals hypotension induced by LPS or TNF-α can be reversed by NOS inhibitors and reinitiated by L-arginine (Kilbourn et. al, PNAS, 87, 3629- 32, 1990). Conditions which lead to cytokine-induced hypotension include septic shock, hemodialysis (Beasley and Brenner, Kidney Int., 42, Suppl., 38, S96--S100, 1992) and IL-2 therapy in cancer patients (Hibbs et. al, J. Clin. Invest., 89, 867-77, 1992). NOS 2 is implicated in these responses, and thus the possibility exists that a NOS inhibitor would be effective in ameliorating cytokine-induced hypotension. Recent studies in animal models have suggested a role for NO in the pathogenesis of inflammation and pain and NOS inhibitors have been shown to have beneficial effects on some aspects of the inflammation and tissue changes seen in models of inflammatory bowel disease, (Miller et. al, J. Pharmacol Exp. Ther., 264, 11-16, 1990) and cerebral ischemia and arthritis (lalenti et. al, Br. J. Pharmacol ., 110, 701-6, 1993; Stevanovic- Racic et al, Arth. & Rheum., 37, 1062-9, 1994). Moreover transgenic mice deficient in NOS 1 show diminished cerebral ischemia (Huang et. al, Science, 265, 1883-5, 1994).
Further conditions where there is an advantage in inhibiting NO production from L-arginine include therapy with cytokines such as TNF, IL-1 and IL-2 or therapy with cytokine-inducing agents, for example 5, 6-dimethylxanthenone acetic acid, and as an adjuvant to short term immunosuppression in transplant therapy. In addition, compounds which inhibit NO synthesis may be of use in reducing the NO concentration in patients suffering from inflammatory conditions in which an excess of NO contributes to the pathophysiology of the condition, for example adult respiratory distress syndrome (ARDS) and myocarditis. There is also evidence that an NO synthase enzyme may be involved in the degeneration of cartilage which takes place in autoimmune and/or inflammatory conditions such as arthritis, rheumatoid arthritis, chronic bowel disease and systemic lupus erythematosis (SLE).
5 It is also thought that an NO synthase enzyme may be involved in insulin- dependent diabetes mellitus. Therefore, a yet further aspect of the present invention provides thiazine and thiazolone derivatives or salts thereof in the manufacture of a medicament for use in cytokine or cytokine-inducing therapy, as an adjuvant to short term l o immunosuppression in transplant therapy, for the treatment of patients suffering from inflammatory conditions in which an excess of NO contributes to the pathophysiology of the condition.
SUMMARY OF THE INVENTION
15
The invention disclosed herein encompasses compounds of
Formula I
Figure imgf000007_0001
I
5 and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These diseases and disorders include hypotension, septic shock, toxic shock syndrome, hemodialysis, 0 IL-2 therapy such as in in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn, eczema or psoriasis and respiratory conditions such as bronchitis, asthma, oxidant-induced lung injury and acute respiratory distress (ARDS), glomerulonephritis, inflammatory sequelae of viral infections, myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension, retinitis and uveitis, type 1
5 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis. Compounds of Formula I are also usful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, mulitple sclerosis, Korsakoff s disease, imbecility related to l o cerebral vessel disorder, NO mediated cerebral trauma and related sequelae, ischemic brain edema, sleeping disorders, schizophrenia, depression, pre-menstrual syndrome (PMS), anxiety, drug addiction, pain, migraine, immune complex disease, as immunosupressive agents, acute allograft rejection, infections caused by invasive microorganisms
15 which produce NO and for preventing or reversing tolerance to opiates and diazepines.
DETAILED DESCRIPTION OF THE INVENTION
20 The invention disclosed herein encompasses compounds of
Formula I
Figure imgf000008_0001
I
and pharmaceutically acceptable salts thereof wherein 30 side a or side b has a double bond, n is O, 1, 2, 3 or 4
X is selected from C2, O, S and NH,
Rl, R2 and R3 are each independently selected from the group consisting of
(a) hydrogen, (b) Ci-i2alkoxy,
(c) Ci-l2alkylS(0)k wherein k is 0, 1 or 2,
( ) mono Ci-l2alky] amino,
(e) (di-C i-l 2alkyl)amino, ω C l - 12alky lcarbonyl,
(g) Ci-I2alkyl,
(h) C2-12alkenyl,
(i) C2-12alkynyl,
(j) C5-10cycloalkyl,
(k) hetero C5-iθcycloalkyl,wherein the hetero C5-lθcycloalkyl optionally contains 1 or 2 heteroatoms selected from S, 0 and N,
(1) aryl, selected from phenyl or naphthyl,
(m) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) benzimidazolyl,
(2) benzofuranyl,
(3) benzooxazolyl,
(4) furanyl,
(5) imidazolyl,
(6) indolyl,
(7) isooxazolyl,
(8) isothiazolyl,
(9) oxadiazolyl,
(10) oxazolyl,
(ID pyrazinyl,
(12) pyrazolyl,
(13) pyridyl,
(14) pyrimidyl,
(15) pyrrolyl,
(17) isoquinolyl,
(18) tetrazolyl,
(19) thiadiazolyl,
(20) thiazolyl, (21) thienyl, and
(22) triazolyl, (n) amino,
(o) oxo, (p) C(0)OH,
(q) C(0)OR6, R6 is selected from hydrogen, phenyl, cyclohexyl or Ci-6alkyl, each of (b) to (m) being optionally mono or di- substituted the substituents being independently selected from (l) hydroxy,
(2) carboxy,
(3) -NR6R7, where R7 is selected from hydrogen, phenyl, cyclohexyl or Cl-6alkyl,
(4) -OR6, (5) -C02R6,
(6) -S(0) R6,
(7) halo selected from F, Cl, Br and I,
(8) -C(=NR6)-NHR7, (9)-S-C(=NR6)-NHR7, provided that when Rl, R2 or R3 is hydroxy, amino, mono Ci_4alkylamino or (di-Ci-4alkyl)amino, said Rl, R2 or R3 must not reside alpha to a hetero atom of the ring on which it resides, or when two members of the group Rl , R2 and R3 reside on the same carbon atom of Formula I, or two of the group Rl , R2 and R3 reside on adjacent atoms of Formula I, said two members may optionally be joined, such that together with the carbon atom to which they are attached there is formed a saturated or unsaturated monocyclic ring of 5, 6 or 7 atoms, said monocyclic ring optionally containing up to three hetero atoms selected from N, O or S, or when a member of the group Rl, R2 and R3 resides on an atom adjacent to the N on which R4 resides, said member may optionally be joined with R4, such that together with the N on which R4 resides and the carbon on which said member resides there is formed a saturated or unsaturated monocyclic heterocycle of 5, 6 or 7 atoms, said monocycle optionally containing up to three hetero atoms selected from N, O or S, R5 are each independently selected from the group consisting of
(a) hydrogen,
(b) linear and branched C l - 12alkyl, optionally mono or di- substituted, the substituents being independently selected from
(1) hydroxy,
(2) carboxy,
(3) -NR6R7,
(4) -OR6, (5) -C02R6,
(6) -S(0)kR6,
(7) halo selected from F, Cl, Br and I,
(8) phenyl, optionally mono or di-substituted with hydroxy, halo, Ci-4alkyl, or Ci-4alkoxy, (c) -CONR8R9, where R8 and R9 are each independently hydrogen, phenyl, cyclohexyl or Ci-6alkyl, said Cl-6alkyl optionally substituted by
(1) hydroxy,
(2) amino, (3) carboxy,
(4) -NRioRl 1, wherein Rio and Rl 1 are each independently H, Ci-6alkyl, phenyl or benzyl,
(5) -OR10,
(6) -CO2R10, (7) -S(O)mRl0, where m is 0, 1 or 2,
(8) halo selected from F, Cl, Br and I,
(9) optionally substituted aryl wherein aryl and aryl substituents are as defined above, (10) optionally substituted heteroaryl wherein heteroaryl and heteroaryl substituents are as defined above,
(11) optionally substituted C5-10cycloalkyl wherein cycloalkyl and cycloalkyl substituents are as defined above,
(12) optionally substituted hetero C5-lθcycloalkyl wherein hetero cycloalkyl and hetero cycloalkyl substituents are as defined above, (d) -CSNR8R9, (e) -COR9,
(f) -C02R9,
(g) -CSR9, (h) phenyl,
(i) cyclohexyl, provided that R4 is present only when side a is a single bond and side b is a double bond, and further provided that when n is 0 or 1, X is S and Rl, R2, R3» and R4 are hydrogen, then R5 is other than hydrogen or methyl.
Within this embodiment is the genus wherein n is 0, 1, 2, 3 or 4
X is selected from O, S and NH,
Rl, R2 and R3 are each independently selected from the group consisting of
(a) hydrogen, (b) Cl-6alkoxy,
(c) Cl-6alkylamino,
(d) Ci-6alkylcarbonyl,
(e) Cl-6alkyl,
(f) C2-6alkenyl, (g) C5, C6 or C7cycloalkyl,
(h) hetero C5 or C6 cycloalkyl, wherein the hetero C5 or C6 cycloalkyl optionally contains 1 heteroatom selected from S,
O and N, (i) aryl, selected from phenyl or naphthyl, (j) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) furanyl,
(2) pyrazinyl, (3) pyrazolyl,
(4) pyridyl,
(5) pyrimidyl,
(6) thiazolyl,
(7) thienyl, and (8) triazolyl, each of (b) to (j) being optionally mono or di- substituted the substituents being independently selected from
(1) hydroxy,
(2) carboxy, (3) -NR6R7, where R6 and R7 are each independently hydrogen, phenyl or Ci-4alkyl,
(4) -OR6,
(5) -C02R6,
(6) -S(0)kR6, where k is 0, 1 or 2, (7) halo selected from F, Cl, Br and I,
(8) -C(=NR6)-NHR7, (9)-S-C(=NR6)-NHR7, or when two members of the group Rl, R2 and R3 reside on the same carbon atom of Formula I, or two of the group Rl, R2 and R3 reside on adjacent atoms of Formula I, said two members may optionally be joined, such that together with the carbon atom to which they are attached there is formed a saturated or unsaturated monocyclic ring of 5, 6 or 7 atoms, said monocyclic ring optionally containing up to three hetero atoms selected from N, O or S, or when a member of the group Rl, R2 and R3 resides on an atom adjacent to the N on which R4 resides, said member may optionally be joined with R4, such that together with the N on which R4 resides and the carbon on which said member resides there is formed a saturated or unsaturated monocyclic heterocycle of 5, 6 or 7 atoms, said monocycle optionally containing up to three hetero atoms selected from N, O or S, R5 are each independently selected from the group consisting of
(a) hydrogen,
(b) linear and branched Cl-6alkyl, optionally mono or di- substituted, the substituents being independently selected from (1) hydroxy,
(2) carboxy,
(3) -NR6R7,
(4) -OR6,
(5) -C02R6, (6) -S(0)kR6, where k is 0, 1 or 2,
(7) halo selected from F, Cl, Br and I,
(c) -CONR8R9, where R8 and R9 are each independently hydrogen, phenyl, cyclohexyl or Cl-4alkyl, said Cl-4alkyl optionally substituted by (1) hydroxy,
(2) amino,
(3) carboxy,
(4) -NRioRl 1, wherein Rio and Rl 1 are each independently H, Ci-4alkyl, phenyl or benzyl, (5) -ORlO,
(6) -CO2R10,
(7) -S(O)mRK), where m is 0, 1 or 2,
(8) halo selected from F, Cl, Br and I,
(9 optionally substituted aryl wherein the aryl and substituents are as defined above,
(10) optionally substituted heteroaryl wherein the heteroaryl and substituents are as defined above,
(11) optionally substituted C5 or C6 cycloalkyl wherein the cycloalkyl and substituents are as defined above, (12) optionally substituted hetero C5 or C6 cycloalkyl wherein the hetero cycloalkyl and substituents are as defined above, (d) -CSNR8R9, (e) -COR9,
(f) -C02R9,
(g) -CSR9, (h) phenyl,
(i) cyclohexyl, such that R4 is present only when side a is a single bond and side b is a double bond.
Within this genus is the class of compounds of the formulae Ia and lb or tautomers thereof
R5
Figure imgf000015_0001
la lb wherein n is 0, 1 or 2
X is selected from O, S and NH, Rl and R2 are each independently selected from the group consisting of
(a) hydrogen,
(b) linear and branched C 1 ~4alkyl, said C 1 -4alkyl being optionally mono or di- substituted the substituents being independently selected from
(1) carboxy,
(2) -NHR7, wherein R6 and R7 are each independently hydrogen or Cl-3alkyl,
(3) -OR6,
(4) -C02R6, (5) -S(0)kR6, where k is 0, 1 or 2,
R4 is selected from the group consisting of
(a) hydrogen,
(b) -CONHR9, where R9 is hydrogen or Cl-3alkyl, said Cl
3 alkyl optionally substituted by
(1) hydroxy,
(2) amino,
(3) carboxy,
(4) -NRioRl 1, wherein Rio and Rl 1 are each independently C 1-3 alkyl,
(5) -ORio,
(6) -CO2R10,
(7) -S(O)mRl0, where m is 0, 1 or 2, (9) halo selected from F, Cl, Br and I,
(c) -CSNHR9;
(d) Ci-3alkyl;
R5 is selected from the group consisting of
(a) hydrogen,
(b) -CONHR9,
(c) -CSNR8R9.
(d) Cl-3alkyl.
Within this class are the compounds of the formulae
Figure imgf000016_0001
and tautomers thereof.
Illustrating the invention are Examples 1 through 41 disclosed hereinunder.
As appreciated by those of skill in the art the additional carbon members of the Formula I ring, "( )n" and definitions "CH2" and "NH" under X, provide available positions for the substituents Rl, R2 or 3.
When any variable (e.g. Rl, R2, R3, R4, R5, 6, R7, R8, Ra, Rb, k, n, p etc.) occurs in any position of a compound of Formula I, it's definition on each occurrence is independent of it's definition at every occurrence.
As appreciated by those of skill in the art, compounds of Formula I include those wherein there is a double bond at side a or b such as shown in Ia and lb or tautomeric forms thereof
Figure imgf000017_0001
la lb
As also appreciated by those of skill in the art, compounds of Formula 1 wherein or when two members of the group Rl, R2 and R3 are joined together to form a ring are intended to include such formulae as:
Figure imgf000017_0002
wherein p is 0, 1, or 2 and n is defined as above and wherein the second ring may contain up to three hetero atoms selected from N, O or S
Similarly, compounds of Formula I wherein a member of the group Rl, R2 and R3 resides on an atom adjacent to the N on which R4 resides and forms a ring therewith may be illustrated by:
Figure imgf000018_0001
wherein p is 0, 1, or 2 and wherein the second ring may contain up to three hetero atoms selected from N, O or S
For purposes of this specification alkyl is defined to include linear, branched, and cyclic structures, with Cl-6alkyl including methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Similarly, Ci-6alkoxy is intended to include alkoxy groups of from 1 to 6 carbon atoms of a straight, branched, or cyclic configuration. Examples of lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like. Likewise, C 1-6 alkylthio is intended to include alkylthio groups of from 1 to 6 carbon atoms of a straight, branched or cyclic configuration. Examples of lower alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration, the propylthio group signifies -SCH2CH2CH3. Heteroaryl includes furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1,2,3-triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,3,4-triazole, 1,2,5-oxadiazole, 1,2,5-thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,4,5-tetrazine, and the like.
As oudined in the summary of the invention, the compounds of the instant invention are useful for in the treatment of a number of NOS implicated diseases. The implication of these diseases is well documented in the literature. For example, with regard to psoriasis, see Ruzicka et. al, J. Invest. Derm., 103: 397 (1994) or Kolb-Bachofen et. al, Lancet, 344: 139 (1994) or Bull, et al., J. Invest. Derm., 103:435(1994); with regard to uveitis, see Mandia et. al, Invest Opthalmol., 35: 3673-89 (1994); with regard to type 1 diabetes, see Eisieik & Leijersfam, Diabetes & Metabolism, 20: 116-22 (1994) or Kroncke et. al, BBRC, 175: 752-8 (1991) or Welsh et. al, Endocrinol, 129: 3167-73 (1991); with regard to septic shock, see Petros et. al, Lancet, 338: 1557-8 (1991),Thiemermann & Vane, Eur. J. Pharmacol., 211: 172-82 (1992), or Evans et. al, Infec. Imm., 60: 4133-9 (1992), or Schilling et. al, Intensive Care Med., 19: 227-231 (1993); with regards to pain, see Moore et. al, Brit. J. Pharmacol., 102: 198-202 (1991), or Moore et. al, Brit. J. Pharmacol., 108: 296-97 (1992) or Meller et. al, Europ. J. Pharmacol, 214: 93-6 (1992) or Lee et. al, NeuroReport, 3: 841-4 (1992); with regard to migraine, see Olesen et. al, TIPS, 75: 149- 153 (1994); with regard to rheumatoid arthritis, see Kaurs & Halliwell, FEBS Letters, 350: 9-12 (1994); with regard to osteoarthritis, see Stadler et. al, J. Immunol, 147: 3915-20 (1991); with regard to inflammatory bowel disease, see Miller et. al, Lancet, 34: 465-66 (1993) or Miller et. al, J. Pharmacol. Exp. Ther., 264: 11-16 (1993); with regard to asthma, see Hamid et. al, Lancet, 342: 1510-13 (1993) or Kharitonov, et. al, Lancet, 343: 133-5 (1994); with regard to Immune complex diseases, see Mulligan et. al, Br. J. Pharmacol., 107: 1159-62 (1992); with regard to multiple sclerosis, see Koprowski et. al, PNAS, 90: 3024-7 (1993); with regard to ischemic brain edema, see Nagafuji et. al, Neurosci., 147: 159- 62 (1992) or Buisson et. al, Br. J. Pharmacol., 106: 766-67 (1992) or Trifiletti et. al, Europ. J. Pharmacol, 218: 197-8 (1992); with regard to toxic shock syndrome, see Zembowicz & Vane, PNAS, 89: 2051-55 (1992); with regard to heart failure, see Winlaw et. al, Lancet, 344: 373- 4 (1994); with regard to ulcerative colitis, see Boughton-Smith et. al, Lancet 342: 338-40 (1993); and with regard to atherosclerosis, see White et. al, PNAS, 91: 1044-8 (1994); with regard to glomerulonephritis, see Mϋhl et. al, Br. J. Pharmcol, 112: 1-8 (1994); with regard to paget's disease and osteoporosis, see Lowick et. al, J. Clin. Invest., 93: 1465-72 (1994); with regard to inflammatory sequelae of viral infections, see Koprowski et. al, PNAS, 90: 3024-7 (1993); with regard to retinitis, see Goureau et. al, BBRC, 186: 854-9 (1992); with regard to oxidant induced lung injury, see Berisha et. al, PNAS, 91: 744-9 (1994); with regard to eczema, see Ruzica, et al., J. Invest. Derm., 103:395(1994); with regard to acute allograft rejection, see Devlin, J. et al., Transplantation, 58:592- 595 (1994); and with regard to infection caused by invasive microorganisms which produce NO, see Chen, Y and Rosazza, J.P.N., Biochem. Biophys. Res. Comm., 203:1251-1258(1994).
It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are
5 meant to also include the pharmaceutically acceptable salts.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. l o Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide
15 pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium
20 phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the
25 gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
3 o Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil. Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxy-
5 propylmethycellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide l o with long chain aliphatic alcohols, for example heptadecaethylene- oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example
15 polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p- hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
20 Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth
25 above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granule1- suitable for preparation of an aqueous suspension by the addition of wat provide the active
30 ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. The pharmaceutical compositions of the invention may also be in the form of an oil-in- water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy beans, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Compounds of formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the
5 above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day, preferably 2.5 mg to 1 g per patient per day. l o The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an
15 appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
20 It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
25
Assay Protocol for NOS activity
NOS activity is measured as the formation of L-[2,3,4,5- 3H]Citrulline from L-[2,3,4,5-3H]Arginine. The incubation buffer (100 30 μL) contained; 100 mM TES, pH 7.5, 5 μM FAD, 5 μM FMN, 10 μM BH4, 0.5 mM NADPH, 0.5 mM DTT, 0.5 mg/mL BSA, 2 mM CaC12, 10 μg/mL calmodulin (bovine), 1 μM L-Arg, 0.2 μCi L-[2,3,4,5-3H]Arg, and the inhibitor in aqueous DMSO (max. 5 %). The reaction is initiated by addition of enzyme. Incubations are performed at room temperature for 30 minutes and stopped by the addition of an equal volume of quenching buffer consisting of 200 mM sodium citrate, pH 2.2, 0.02% sodium azide. Reaction products are separated by passing through a cation exchange resin and quantitated as cpm by scintillation counting. Percent inhibition is calculated relative to enzyme incubated without inhibitor according to: % inhibition = 100 x (cpm L-[2,3,4,5-3H]Cit with inhibitor / cpm L-[2,3,4,5-3H]Cit without inhibitor).
Illustrative of the utility of the compounds of Formula I is the ability of such compounds to inhibit NO synthase as shown in Tables 1-6 and as measured by the assay described above:
TABLE 1
Figure imgf000024_0001
TABLE 2
Figure imgf000025_0001
TABLE 3
15
Figure imgf000025_0002
30 TABLE 4
Figure imgf000026_0001
20
25
30 TABLE 5
Figure imgf000027_0001
25
30 TABLE 6
Figure imgf000028_0001
TABLE 7
Inhibition of NO Synthases by Cyclic Isothioureas
Example iNOS
No. ecNNOS ncNOS IC50 (uM) IC50 (uM) IC50 (uM)
1 0.018 0.065
12 0.029
3.03 >50
13 <0.5
1.43 12.4
14 0.3
16 >50
15 ND
<50 ND
16 ND
ND ND
19 ND
13 50
20 9.6
12.2 >50 5 21 2.7 1.8 0.59
23 22 >25 6.7
24 1.25 >25 6.1
25 0.34 7.4 0.54
26 0.012 0.28 0.02
27 0.0045 0.34 0.023
28 0.169 40.5 4.85
29 0.028 1.4 0.252
30 0.0141 0.68 0.052
31 0.015 0.094 0.021
32 0.073 1.38 0.073
33 0.016 0.5 0.024
34 1.05 5.47 0.083
35 0.007 <0.1 <0.1
36 0.056 <0.5 <0.1
37 >50 >50 >50
38 0.66 2.5 0.1
39 0.019 <0.1 <0.1
40 0.33 1.8 0.1
41 21 24.3 1
Several methods for preparing the compounds of this invention are illustrated in the following schemes and examples. Some of the compounds are known in the literature. A limited number of substituted thiazole and thiazoline derivatives are reported to be inhibitors of NO synthase. See WO 94/12165 and J. Biol. Chem. 1994, 289, 26669-76. Unless otherwise stated, starting materials were obtained from commercial sources. In one method illustrated by example 1 (Scheme 1: path a), these compounds are prepared by reacting an aminoalkyl halide with potassium thiocyanate and the resulting aminoalkylthiocyanate is cyclized in the presence of a base or a cyanide ion. The aminoalkyl halides starting materials are commercially available or they can be prepared by the methods known to those skilled in the art. Alternatively the amine substrate for the displacement reaction may contain a different leaving group such as a mesylate or a tosylate which are prepared fron the corresponding alcohol using the methods described in March J. Advanced Organic Chemistry, 3rd ed., John Wiley & Sons, New York, p. 444 (1985). In an alternative method of synthesis as shown in scheme 1: path b, and illustrated by example 2, the amine is first reacted with an acylating agent such as an alkyl, aryl or acyl isothiocyanate and the resulting thiourea is cyclized upon heating with or without a base 5 catalyst. If an acylisothiocyanate is used (Example 19) a 2- acylaminothiazine product is obtained.
Path c of scheme 1 shows a third way for forming the desired ring structures. In this method the aminoalcohol, halide or other l o suitable derivative is reacted with carbon disulfide to form the heterocyclic ring system with a thiocarbonyl group. Methylation and displacement of the resulting methylthio group with ammonia or an amine gives the desired 2-amino substituted heterocycle.
15
20
25
30 SCHEME 1
Figure imgf000031_0001
Two methods for the preparation of cyclic compounds from a thiourea are shown in shceme 2 and illustrated by examples 21 and 22. Thus reaction of a thiourea with 1,2-dibromoethane can give a thiazoline (Example 21). Alternatively if the thiourea contains a double bond, cyclization in the presence of an acid can result in the desired ring. Alternatively iodocyclization (Example 22) can lead to an iodo derivative which can be further modified by hydrolysis or by displacement reactions as shown in examples 23 and 24. SCHEME 2
Figure imgf000032_0001
X = H or I
The 2-aminothiazoline (and other rings) prepared by methods shown in schemes 1 or 2 can be further modified, for example by acylation (scheme 3). Thus reaction of 2-Amino-5,6-dihydro-4H-l,3- thiazine with an acid chloride or anhydride optionally in the presence of a base gives a 2-acylamino analog. Other acylation procedures as described in March J., Advanced Organic Chemistry, 3rd ed., John Wiley & Sons, New York, (1985) may also be used. If an isocyanate or an isothiocyanate (Example 12) is used for acylation, the product is a urea or a thiourea. Alternatively ureas or a thioureas can also be prepared by reacting the amino compound with phosgene, thiophosgene, or other carbonyl tranfer reagents such as carbonyldiimidazole or thiocarbonyldiimidazole followed by reaction with another amine (Example 15) . SCHEME 3
Figure imgf000033_0001
Figure imgf000033_0002
The invention will now be illustrated by the following non- limiting examples in which, unless stated otherwise:
all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm. Hg) with a bath temperature of up to 60°C; the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only; melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations; the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data; yields are given for illustration only; when given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 400 MHz or 500 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; ξ__c.: in addition "Ar" signifies an aromatic signal; chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (miHigrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)). The preparation and biological properties of isothioureas have been reported in the literature (Schroeder, Chem, Revs., 1955, 55 , 181; Doherty etal, J. Am. Chem. Soc, 1957, 79, 5667; and Brand and Brand, Org. Synth., 1942, 22, 59; Smirk etal, Brit. Med. J., 1941, 510- 11; J. Physiol., 1942, 100, 474-483; Lancet, 1942, 301-303; J Physiol., 1943, 101, 379-388; Fastier, Brit. J. Pharmacol., 1948, 3, 198).
EXAMPLE 1
2- Amino-5.6-dihvdro-4H- 1.3-thiazine.
A flask containing 8.76 g (40 mmol) of 3- bromopropylamine hydrobromide and 3.89 g (40 mmol) of potassium thiocyanate in 25 mL of water was heated in a 100 βC bath. After heating overnight most of the water had evaporated. The reaction was cooled and the remaining volatiles were removed in vacuo. The residue was treated with 100 mL of hot absolute EtOH, the undissolved solid (KBr) was filtered. Upon cooling the filtrate white crystals were formed. The crystals were were filtered, washed with cold EtOH and dried to obtain 6.2 g of solid. In a 1 lit 3- neck flask equipped with an addition funnel and a gas outlet tube, containing 2.05 g (31.5 mmol) of KCN in 500 mL of water a solution of 6.2 g of the solid obtained above in 125 mL of water was dropwise added. After stirring the reaction mixture overnight, it was acidified by adding 48% HBr. Since HCN gas may be produced during this operation the escaping gases were passed through a trap of 5N NaOH. The resulting yellow solution was heated in a 40 oC bath for 4 h, then 4 g of activated charcoal was added and the mixture was kept stirred at 40 oC for 2 h more. The reaction was filtered through a pad of celite and the filtrate was concentrated. The remaining water in the residue was removed by adding MeOH and concentration. The residual solid was treated with 60 mL of MeOH and filtered to remove KBr. The filtrated was reduced to about 20 mL and allowed to cool to RT. The solution was diluted with EtOAc (50 mL) and on standing crystals were formed. The solid was filtered, washed with EtOAc and dried to isolate 3.2 g of the title compound. An additional 0.97 g (53% total) of thtitle compound was obtained from the filtrate by concentration and cooling.
1H NMR (CDCI3) δ: 1.79 (m, 2 H), 3.0 (m, 2 H), 3.48 (m, 2 H). Mass Spectrum m/e = 117 (M+l).
EXAMPLE 2
2-Methylamino-5.6-dihvdro-4H- 1.3-thiazine.
A mixture of 0.19 g (0.87 mmol) of 3-bromopropylamine hydrobromide in 3 mL of toluene containing 63 uL (0.92 mmol) of methylisothiocyanate and 0.16 uL (0.92 mmol) of diisopropylethylamine was heated to reflux. After 30 min the starting hydrobromide had dissolved and a yellow oil separated. The reaction mixture was cooled and extraced with water. The combined aqueous extract was washed with ether. The water layer was made basic (pH = 10) by adding 2N NaOH and then extracted with CH2CI2. The CH2CI2 layer was washed with brine and dried over Na2S04 and the filtrate was concentrated to provide 68 mg (60 %) of the title compound. lH NMR (CDCI3) δ: 1.80 (m, 2 H), 2.77 (s, 3 H), 3.0 (m, 2 H), 3.54 (m, 2 H).
Mass Spectrum m/e = 131(M+1).
Compounds of Examples 3- 11 were prepared by following the procedure of Example 2 by substituting an appropriate isothiocyanate for methylisothiocyanate.
EXAMPLE 3 2-Ethylamino-5.6-dihydro-4H- 1.3-thiazine.
iH NMR (CDC13) δ: 1.11 (t, 3 H), 1.80 (m, 2 H), 3.0 (t, 2 H, J = 6 Hz), 3.20 (q, 2 H, J = 7 Hz), 3.52 (m, 2 H). Mass Spectrum m/e = 145(M+1).
EXAMPLE 4
2-Propylamino-5.6-dihydro-4H- 1.3-thiazine. Mass Spectrum m/e = 159(M+1).
EXAMPLE 5
2-(2-Methylethyl)amino-5.6-dihydro-4H- 1.3-thiazine. Mass Spectrum m/e = 159(M+1).
EXAMPLE 6
2-Butylamino-5.6-dihydro-4H- 1.3-thiazine. Mass Spectrum m/e = 173(M+1).
EXAMPLE 7
2-(2.2-Dimethylethyl)amino-5.6-dihvdro-4H- 1.3-thiazine. Mass Spectrum m/e = 173(M+1).
EXAMPLE 8
2-(Cyclohexyl)amino-5.6-dihydro-4H- 1.3-thiazine. Mass Spectrum m/e = 199(M+1).
EXAMPLE 9
2-Phenylamino-5.6-dihvdro-4H- 1.3-thiazine.
EXAMPLE 10 2-(3-Dimethylaminpropy amino-5.6-dihydro-4H- 1.3-thiazine. Mass Spectrum m/e = 202(M+1).
EXAMPLE 11 2-(2-Dimethylaminoethv amino-5.6-dihvdro-4H- 1.3-thiazine.
iH NMR (CD30D) δ: 2.24 (m, 2 H), 3.31 (s, 6 H), 3.31 (m, 2 H), 3.62 (t, 2 H), 3.71 (t, 2 H), 3.88 (t, 2 H).
EXAMPLE 12
2-(3-Diethylaminopropylamino-thiocarbonyl-aminoV5.6-dihydro-4H- 1.3-thiazine.
To a solution of 80 mg (0.615 mmol) of 3- diethylaminopropylamine in 1 mL of CHCI3 and 1 mL of saturated NaHCθ3 was added 47 uL (0.615 mmol) of thiophosgene. After vigorously stirring the mixture for 0.5 h, the layers were separated and the aqueous phase was extracted with CH2CI2. The combined organic phase was washed with brine, dried and concentrated. The residue was dissolved in 1 mL of DMF and the solution was added to 0.1 g (0.512 mmol) of 2-amino-5,6-dihydro-4H-l,3-thiazine hydrobromide in 1 mL of DMF and 86 uL (0.615 mmol) of E13N. The mixture was heated at 60 βC for 4 h, then allowed to cool to room temperature over night. The reaction was partitioned between water and EtOAc. The EtOAc layer was washed with water, brine, dried and the filtrate was concentrated. The residue was purified by prep TLC using 30 % MeOH-EtOAc to isolate 48 mg (33 %) of the title compound. Mass Spectrum m/e = 289, 196, 173, 157,125, 100.
EXAMPLE 13
2-(3-Dimethylaminopropylamino-thiocarbonyl-aminoV5.6-dihvdro-4H- 1.3-thiazine. iH NMR (CDC13) &1.64 (m, 2 H), 1.78 (m, 2 H), 2.17 (s, 6 H), 2.31 (t, 2 H, J = 7 Hz), 3.0 (m, 2 H), 3.25 (t, 2 H, J = 7 Hz), 3.52 (m, 2 H).
Mass Spectrum m/e = 261, 216, 186, 173, 159.
EXAMPLE 14
2-(2-Dimethylaminoethylamino-thiocarbonyl-amino)-5.6-dihydro-4H- 1.3-thiazine.
By substituting 2-dimethylaminoethylamine for 3- diethylaminopropylamine in example 12 the title compound was obtained.
Mass Spectrum m/e = 247, 213, 202, 159.
EXAMPLE 15
2-r3-Diethvlaminopropyl)methylamino-thiocarbonvl-amino)-5.6- dihvdro-4H- 1 ,3-thiazine.
A solution of 74 mg (0.38 mmol) of 2-amino-5,6-dihydro- 3H-l,3-thiazine hydrobromide in 2 mL of DMF was treated with 63 uL (0.45 mmol) of E13N and 67 mg (0.38 mmol) of 1,1 - thiocarbonyldiimidazole. After stirring for 1 h, 66 mg (0.45 mmol) of N.N-diethyl-N'-methyl- 1 ,3-propanediamine was added and the mixture was heated to 50 °C. After 2 h the reaction was cooled and partitioned between water and EtOAc. The aqueous layer was extraced with EtOAc and each EtOAc layer was washed with water, brine, dried, combined and concentrated. The residue was purified by prep TLC using 30 % MeOH- EtOAc to isolate 39 mg (34 %) of the title compound.
Mass Spectrum m/e = 303, 170, 145, 125. The compounds of examples 16-18 were prepared by the procedure of example 15 and substituting the appropriate diamine for N,N-diethyl-N'-methyl- 1 ,3-propanediamine.
EXAMPLE 16
2-(2-Dimethylaminoethv ethylamino-thiocarbonyl-aminoV5.6-dihvdro- 4H-1.3-thiazine.
Mass Spectrum m/e = 275,159,145, 142, 129, 117.
EXAMPLE 17
2-(2-Diethylaminoethyl')ethylamino-thiocarbonyl-aminoV5.6-dihydro- 4H-L3-thiazine.
Mass Spectrum m/e = 303, 170, 159, 145, 143, 118, 102(M+1).
EXAMPLE 18
2-(2-Dimethylaminoethyl)phenylmethylamino-thiocarbonyl-amino>-5.6- dihydro-3H- 1.3-thiazine.
Mass Spectrum m/e = 337, 292, 207, 191, 177, 159.
EXAMPLE 19 2-Benzoylamino-4H-3.1-benzothiazine Step A: l-(2-BromomethvDphenyl-3-benzoyl-thiourea.
To a solution of 0.223 g (1.81 mmol) of 2-aminobenzyl alcohol in 7 mL of toluene was added 0.24 mL (1.81 mmol) of benzoyl isothiocayante. After stirring the mixture under N2 atmosphere for 2 h, the reaction was partitioned between water and EtOAc. The water layer was extracted with EtOAc and each EtOAc layer was washed with brine, dried, combined and concentrated to obtain 0.449 g of a residue. A solution of this residue in 8 mL of MeCN was added to a solution of dibromotriphenylphosphorane prepared by adding bromine to 0.53 g (2 mmol) of triphenylphosphine in 4 mL of MeCN. After stirring the reaction for 1 h the solution was diluted with EtOAc, washed with water, brine, dried and concentrated. The residue was chromatographed on a flash column using 20% EtOAc-Hexane to furnish 0.16 g (25%) of the title compound.
iH NMR (CDC13) δ: 4.03 (s, 2 H), 7.1-7.6 (m, 7 H), 8.2 (d, 2 H, J = 7 Hz).
Step B: 2-Benzoylamino-4H-3.1-benzothiazine.
A solution of 0.158 g (0.45 mmol) of 1 -(2- bromomethyl)phenyl-3-benzoyl-thiourea (from step A) in 2 mL of toluene containing 0.13 mL (0.9 mmol) of E13N was heated to reflux. After 4 h the solution was cooled, diluted with EtOAc, washed with water, brine, dried and concentrated. The residue was purified by prep TLC using 50% EtOAc-hexane to isolate 0.107 g (88%) of the title compound.
iH NMR (CDCI3) δ:4.01 (s, 2 H), 7.0-7.5 (m, 7 H), 8.16 (d, 2 H, J = 7
Hz).
Mass Spectrum m/e = 269(M+1).
EXAMPLE 20 2- Amino-4H-3.1 -benzothiazine
A suspension of 98 mg (0.37 mmol) of 2-benzoylamino-4H- 3,1 -benzothiazine (Example 19) in 4 mL of 2 N HCl was heated to reflux. After 24 h at reflux the solution was cooled and washed with Et2θ. The aqueous layer was concentrated to isolate 39 mg (52%) of the title compound as a yellow solid.
iH NMR (CD3OD) δ: 4.27 (s, 2 H), 7.15-7.6 (m, 4 H). Mass Spectrum m/e = 165(M+1).
EXAMPLE 21 5-(2-Thiazolinyl amino-norvaline hydrochloride.
Step A: Na-(t-ButoxycarbonylV5-(2-thiazolinyl)amino-norvaline t- butyl ester.
A solution of 0.118 g (0.33 mmol) of N*-(t- butoxycarbonyl)-5-thioureido-norvaline t-butyl ester (Tet. Lett. 1991, 32, 875-878) in 2 mL of CH2CI2 was treated with 86 uL (1 mmol) of 1,2- dibromoethane and 0.175 mL (1 mmol) of diisopropylemylamine. The vial was tightly capped and heated in a 40 βC bath overnight. The solution was diluted with CH2CI2, washed with water, brine, dried and concentrated. The residue was chromatographed on a flash column using a gradient of EtOAc to 80:19:1 EtOAc:MeOH:Et3N to isolate 54 mg (44%) of the title compound.
iH NMR (CDCI3) δ: 1.42 (s, 9 H), 1.44 (s, 9 H), 1.5-1.9 (m, 4 H), 3.17 (t, 2 H, J = 7 Hz), 3.45 (q, 2 H, J = 7 Hz), 3.64 (t, 2 H, J = 7 Hz), 4.1 (m, 1 H), 5.28 (m, 1 H).
Step B: 5-(2-Thiazolin vDamino-norvaline hy drochloride . HC1 gas was passed through 2 mL EtOAc at 0 "C until it was saturated. This solution (2 mL) was added to 54 mg (0.144 mmol) of N3- (t-butoxycarbonyl)-5-(2-thiazolinyl)amino-norvaline t-butyl ester (from step A) and the mixture was stirred overnight. A white solid was formed. The mixture was diluted with Et2θ, the solid was filtered, washed with Et2θ and dried to isolate 26 mg (71%) of the title compound.
iH NMR (CD3OD) δ: 1.75-2.1 (m, 4 H), 3. 55 (t, 2 H, J = 7 Hz), 3.62 (t, 2H, J = 7 Hz), 4.06 (t, 1 H, J = 7 Hz), 4.12 (t, 2 H, J = 7 Hz).
EXAMPLE 22
5-(S)-2-Iιmno-3-thia-l-aza-bicyclor3.3.0)octane.
Step A: 5-CS )-2-Thioxo-3-thia- 1 -aza-bicyclof 3.3 ,0)octane.
To a solution of 2.5 g (24.5 mmol) of 2-(S)- pyrrolidinomethanol in 10 mL of dry chloroform at 0 °C was bubbled hydrogen chloride gas until saturation. After 10 min. at 0 °C, 3.6 mL (49.4 mmol) of thionyl chloride was introduced and the mixture was refluxed for 90 min. Reaction mixture was cooled to room temperature and stirred overnight (approximately 15 h). Excess thionyl chloride and chloroform were removed under vacuum . The black residue was treated with methanol and successive treatment with charcoal, fϊlteration and concentration furnished 2.3 g of a light yellow hygroscopic solid which was used in the next step.
To a solution of 1.58 g (10 mmol) of 2-(S)-chloromethyl- pyrrolidine (from the above) in 10 mL of dry methylene chloride under nitrogen at 0 °C was added 1.0 ml (15 mmol) of CS2 followed by 4.2 mL (45 mmol) of triethylamine. The reaction mixture was warmed to the room temperature stirred for 3 hours, at which point CS2 and triethylamine were removed under vacuum. The residue was taken up in water and filtered. The solid was repeatedly washed with water and was then dried giving 1.5g (82% yield) of the title compound as a yellowish white solid. iH NMR (500 MHz, CDC13): δ 4.59 ( m, IH), 3,59 (dd, IH), 3.43(dd, IH), 3.29 (m, 2H), 2.20-2.42 (m, IH), 2.18 (m, IH), 1.74 (m, IH).
5
13c NMR (400 MHZ, CDCI3) δ 190.88, 71.88, 46.26, 35.79, 31.35, 28.79.
Step B: 5-(SV2-Imino-3-thia-l-aza-bicvclo(3.3.0 octane.
10.
To a solution of 1 g (6.28 mmol) of 5-(S)-2-Thioxo-3-thia-l- aza-bicyclo(3.3.0)octane in 5 ml of dimethoxyethane at room temperature was added 0.78 ml (12. 4 mmol) of iodomethane and stirred at room temperature for 3 hours. Evaporation of the solvent and excess 15 iodomethane gave the solid residue which was washed with ether giving 1.64 g ( 99% yield) of a solid.
iH NMR (500 MHz, D2O) δ 5.11 ( m, IH), 3.83 (dd, IH), 3.65-3.71 (m, 2H), 2.85 (s, 3H), 2.47-2.60 (m, 2H), 2.32-2.37 (m,2H), 2.00 (m, IH).
20 13C NMR (400 MHZ, D2O) δ 186.70, 77.23, 48.12, 36.87, 29.26, 28.96, 18.10.
Ammonia gas was passed through a solution of 0.303 g (1 mmol) of the solid obatined above in 5 ml of dry methanol at room temperature for 15 min.. The reaction was allowed to proceed overnight
25 (15 hrs). Evaporation of methanol in vacuum gave the title compound.
iH NMR (500 MHz, D2O) δ 4.73 ( m, IH), 3.44-3.56 (m, 4H), 2.37-2.47
(m, 2H), 2.18 (m, IH), 1.81(m, IH).
!3c NMR (400 MHz, D2O) δ 70.78, 44.99, 35.01, 29.69, 28.89.
30
EXAMPLE 23
2-Amino-4-iodomethyl-thiazoline Anhydrous ammonia was passed through a solution of 1.5 g (15.1 mmol) of allyl isothiocyanate in 30 mL of methanol for 20 min. After stirring for 3 h the reaction was complete, so the mixture was concentrated and the residue was chromatographed using 10:10:1 hexane/EtOAc/MeOH to isolate 1.13 g (64%) of allylthiourea.
To a solution of 1.13 g of allylthiourea in 10 mL of CH2CI2 2.5 g (9.67 mmol) of iodine was added. Within 1 h a pale yellow precipitate appeared. After 3 h all the starting material was consumed, the solid was filtered. The filtrate was washed with 10 % NaHSθ3 solution, brine and concentrated to give additional solid which was combined with the yellow solid and washed with chloroform and dried to furnish 1.73 g (74%) of the title compound.
iH NMR (500 MHz, DMSO) δ 9.3 (br s, 2H), 4.35 (m, IH), 3.95 (q, IH),
3.71 (dd, IH), 3.59 (m, IH)..
13c NMR (500 MHz, DMSO) δ 151, 54, 49,10.
EXAMPLE 24
2-Amino-4-hydroxymethyl-thiazoline
To a mixture of 100 mg (0.413 mmol) of 2-amino-4-iodomethyl- thiazoline (from Example 23) in 2.5 mL of nitromethane and 1.5 mL of water was added 137 mg (0.617 mmol) of silver trifluoroacetate. The mixture was vigorously stirred overnight and the next morning it was filtered through celite. Concentration of the filtrate gave 42 mg (76%) of the title compound as a grey solid.
iH NMR (500 MHz, DMSO) δ 10 (s, IH), 9.35 (s, 2H), 4.08 (m, IH),
3.88 (dd, IH), 3.75 (dd, IH), 3.53 (m, IH).
13c NMR (500 MHz, DMSO) δ 172.5, 63, 50.5, 50.
EXAMPLE 25
S-f(2-amino-thiazolino)methvPisothiourea To a mixture of 350 mg (1.45 mmol) of 2-amino-4- iodomethyl-thiazoline (from Example 23) in 3 mL of dioxane were added 473 mg (2.17 mmol) of di-t-butyldicarbonate and 3 mL of saturated NaHC03. The reaction was stirred overnight, filtered and the filtrate was concentrated. The residue was chromatographed using 5:1 hexane/EtOAc to obtain 330 mg (69%) of 2-t-butoxycarbonylamino-4- iodomethyl-thiazoline.
H NMR (500 MHz, CDCI3) δ 4.21 (dd, IH), 4.05 (m, IH), 3.73 (m, IH), 3.4 (dd, IH), 3.3 (t, IH), 1.55 (s, 9H).
To a solution of 120 mg (0.35 mmol) of 2-t- butoxycarbonylamino-4-iodomethyl-thiazoline in 4 mL of absolute EtOH was added 32 mg (0.425 mmol) of thiourea and the solution was stirred overnight. The precipitated solid was filtered and washed with cold EtOH, dried to furnish 20 mg of S-((2-t-butoxycarbonylamino- thiazolino)methyl)isothiourea.
iH NMR (500 MHz, CDCI3) δ 4.0 (m, 2H), 3.85 (br s, IH), 3.45 (br s, lH), 3.3 (br s, IH), 1.55 (s, 9H).
To a solution of 12 mg of S-((2-t-butoxycarbonylamino- thiazolino)methyl)isothiourea in 3 mL of EtOAc, HCl gas was bubbled to saturate it. After stirring the solution overnight the solvent was evaporated and the residual solid was washed with chloroform to furnish
5.1 mg of the title compound. iH NMR (500 MHz, CD3OD) δ4.4 (br s, IH), 4.05 (br s), 3.9 (br s, IH)
3.6 (br s, IH).
1 c NMR (500 MHz, CD3OD) δ 172, 54, 49.6.
EXAMPLE 26
2-Amino-cis-5.6-dimethyl-5.6-dihvdro-4H- 1 ,3-thiazine. methanesulfonic acid sal Step A: 2-Methyl-3-hydroxy-butyronitrile
To a solution of 0.87 mL of cis-2,3-epoxybutane in 20 mL of THF 2.1 g (20 mmol) of LiCN.THF was added and the mixture was heated to reflux. After 2 h, the reaction was cooled to room temperature, poured into water and extracted with Et2θ. The Et2θ solution was washed with water, brine dried and concentrated to yield 0.892 g of the title compound sufficiently pure for use in the next step. 0 Step B: 4-t-Butyloxycarbonylamino-3-methyl-2-butanol
A solution of 0.892 g (9 mmol) of 2-methyi-3 -hydroxy - butyronitrile in 30 mL of Et2θ was treated with 0.683 g (18 mmol) of LiAlH4 and the resulting was heated to reflux for 2 h. The reaction 5 mixmre was cooled in an ice bath and 0.68 mL of water, 0.68 mL of 15% NaOH and 2.04 mL of water were added. The solution was stirred for 0.5 h whereby the aluminium salts coagulated. The solution was filtered through a pad of Na2Sθ4 and the pad was rinsed with more Et2θ. The combined filtrate was concentrated leaving a yellow oil. The oil was ° dissolved in 10 mL of acetonitrile and 10 mL of 1 N NaOH followed by
2.166 g (9.926 mmol) of di-t-butyldicarbonate were added. After stirring for 3 h the reaction mixture was partitioned between water and EtOAc. The organic layer was washed with brine, dried and concentrated. The residue was chromatographed using 30-50% EtOAc-hexane to yield 0.92 5 g of the title compound.
Step C: 3-Methanesulfonyloxy-2-methyl-butylamine hydrochloride.
A solution of 0.323 g (1.773 mmol) of 4-t- 0 butyloxycarbonylamino-3-methyl-2-butanol in 8 mL of CH2CI2 was treated with 0.15 mL (1.95 mmol) of methanesulfonyl chloride and 0.3 mL (2.128 mmol) of Et3N at O °C. After 10 min the ice bath was removed and the solution was allowed to warm to room temperamre over the next 1 h. The reaction was partitioned between water and CH2CI2 and the aqueous layer was extraced with CH2CI2. The combined organic layer was washed with brine, dried and concentrated. The residue was dissolved in 15 mL of EtOAc samrated with HCl gas. After stirring foe 3 h the solution was concentrated leaving 0.455 g of the title compound.
5 Step D: 2- Amino-cis-5.6-dimethyl-5.6-dihydro-4H- 1 ,3-thiazine. methanesulfonic acid salt
To a well stured solution of 0.455 g (2.09 mmol) of 3- methanesulfonyloxy-2-methyl-butylamine hydrochloride in 5 mL of
! 0 CHC13 and 5 mL of saturated NaHCθ3, 0.18 mL (2.3 mmol) of thiophosgene was added. After 50 miin the layers were separated and the aqueous layer was extracted with CH2CI2. The combined organic layer was washed with brine, dried and concentrated. The residue was purified rapidly on a flash column using 30% EtOAc-hexane to furnish 92 mg of
15 the isothiocyanate. This product was dissolved in 6 mL of MeOH which was previously samrated with NH3 and the reaction was stirred overnight. The solution was concentrated leaving 81 mg of the title compound.
20 iH NMR (CD3OD) δ: 1.07 (d, 3 H), 1.37 (d, 3H), 2.38 (m, IH), 2.69 (s, 3H), 3.34 (dd, IH), 3.48 (dd, IH), 3.72 (qd, IH, J=7 and 3.2 Hz).
Mass Spectrum m/e = 145(M+1).
EXAMPLE 27 5
2-Amino-trans-5.6-dimethyl-5.6-dihydro-4H-1.3-thiazine hydrobromide
To a solution of 0.402 g (2.2 mmol) of 4-t- butyloxycarbonylamino-3-methyl-2-butanol (from Example 26, step B) ° in 10 mL of dry acetonitrile was added 1.12 g (2.65 mmol) of dibromotriphenylphosphorane. After stirring for 2 h the reaction mixture was quenched with water, the layers were separated and the aqueous layer was washed with EtOAc. The aqueous layer was concentrated and the residue was dissolved in 2 mL of CHCI3 and 2 mL of samrated NaHCθ3 and 0.095 mL (1.25 mmol) of thiophosgene was added. After stirring for 0.5 h the layers were separated and the aqueous layer was extracted with CH2CI2. The organic layer was washed with brine, dried and concentrated. The residue was purified by prep TLC eluting with 30% EtOAc-hexane to isolate 53 mg of the desired isothiocyanate. This product was dissolved in 5 mL of MeOH samrated wth NH3 and the mixture was stirred for 6 h. The solution was concentrated leaving 23 mg of the desired product.
iH NMR (CD3OD) δ: 1.12 (d, 3 H), 1.41 (d, 3H), 1.95 (m, IH), 3.17 (dd, IH), 3.53 (dd, IH), 3.37 (quintet, IH, J=7 Hz).
Mass Spectrum m/e = 145 (M+l).
EXAMPLE 28
3-Amino-2-thia-4-aza-cis-bicyclo(4.4.0)-dec-3-ene hydrochloride (L- 771tg9 )
The title compound was prepared from cyclohexaneoxide by the procedure of example 26.
iH NMR (CD3OD) δ: 1.1- 2.0 (m, 8 H), 2.3 (m, IH), 3.45 (d, 2H), 3.95 (q, IH, J=4 Hz).
Mass Spectrum m/e = 171 (M+l).
EXAMPLE 29
3-Amino-2-thia-4-aza-cis-bicvclo(4.3.0)-non-3-ene. methane sulfonic acid salt (L-771.598)
The title compound was prepared from cyclopentaneoxide by the procedure of example 26. lH NMR (CD3OD) δ: 1.5- 2.0 (m, 6 H), 2.24 (m, IH), 2.69 (s, 3H), 3.26 (dd, IH), 3.48 (dd, IH), 3.83 (q, IH, J=6 Hz).
Mass Spectrum m/e = 157 (M+l).
EXAMPLE 30
2-Amino-trans-4.5-dimethyl-5.6-dihvdro-4H- 1 ,3-thiazine
Step B: 3-Amino-2-methyl-l-butanol
A solution of 1.737 g (25 mmol) of hydroxylamine hydrochloride in 20 mL of MeOH was neutralized by adding 12.5 mL of 2N NaOH solution and 1.4 mL (10 mmol) of ethyl 2-methylacetoacetate was added. The mixmre was stirred for 1 h and concentrated. The residue was dissolved in water and extracted with EtOAc. The EtOAc solution was washed with brine, dried and concentrated to give 0.974 g of a residue which was dissolved in 20 mL of Et2θ. The solution was cooled in an ice bath and 0.48 g of LiAlH4 was added. The suspension was heated to reflux for 2 h then cooled in ice bath and quenched by sequencially adding 0.48 mL of water, 0.48 mL of 15% NaOH solution and 1.5 mL of water. The mixmre was stirred for 0.5 h to allow the aluminium salts to coagulate. The solution was filtered through Na2Sθ4 and the solid was rinsed with Et2θ. The combined filtrate was concentrated to yield 0.54 g of the title product as an oil which was used in the next step without purification.
Step B: 3-t-Butyloxyamino-2-methyl-l-butanol
A solution of 0.54 g of 3-amino-2-methyl-l-butanol in 6 mL of acetonitrile and 6 mL of IN NaOH was treated with 1.371 g () of dit- butyldicarbonate. After stirring overnight the reaction mixmre was partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc. The combined EtOAc layer was washed with brine, dried and concentrated. The resdue was chromatographed on a flash column using a gradient of 20-30% EtOAc-hexane to isolate 0.26 g of the erythro (faster moving) isomer and 0.14 g of the threo (slower) isomer.
Step C: 2-Amino-trans-4.5-dimethyl-5.6-dihvdro-4H-L3-thiazine. methane sulfonic acid salt
The title compound was prepared from the threo isomer of 3-t-butyloxyamino-2-methyl-l-butanol by the method described in Example 26 steps C and D.
lH NMR (CD3OD) δ: 1.15 (d, 3 H), 1.33 (d, 3H), 1.98 (m, IH), 2.7 (s, 3H), 3.02 (dd, IH), 3.21 (dd, IH), 3.38 (quintet, IH, J=7 Hz).
Mass Spectrum m/e = 145 (M+l).
EXAMPLE 31
2-Amino-cis-4.5-dimethyl-5.6-dihydro-4H-1.3-thiazine. methane sulfonic acid salt
The title compound was synthesized from erythro 3-t- butyloxyamino-2-methyl-l-butanol (Example 30, step B) according to the procedure of Example 26 steps C and D.
lH NMR (CD3OD) δ: 1.08 (d, 3 H), 1.24 (d, 3H), 2.33 (m, IH), 2.7 (s, 3H), 3.06 (dd, IH), 3.27 (dd, IH), 3.72 (qd, IH, J=6.8 and 3.4 Hz).
Mass Spectrum m/e = 145 (M+l).
EXAMPLE 32
4-Amino-3-thia-5-aza-trans-bicvcloC4.4.0)-dec-4-ene. methane sulfonic
Figure imgf000050_0001
Step A: trans- l-Amino-2-hydroxymethyl-cyclohexane hvdrochloride The title compound was prepared fron ethyl cyclohexanone- 2-carboxylate by the method described in Example 31 step A.
Step B: 4-Amino-3-thia-5-aza-trans-bicyclo(4.4.0Vdec-4-ene. methane sulfonic acid salt
This compound was prepared from trans- l-amino-2- hydroxymethyl-cyclohexane hydrochloride by the procedure of Example 26 steps C and D.
lH NMR (CD3OD) δ: 1.1-2.1 (m, 9 H), 2.7 (s, 3H), 3.02 (m, 2H), 3.18 (m, IH).
Mass Spectrum m/e = 171 (M+l).
EXAMPLE 33
l(SV6(RV4-Amino-3-thia-5-aza-cis-bicyclo(4.4.0Vdec-4-ene hvdrochloride (L-770.425)
The title compound was prepared from l(R)-2(S)-l-amino- 2-hydroxymethyl-cyclohexane by the method of Example 26 steps C and D.
lH NMR (CD3OD) δ: 1.4-1.9 (m, 8 H), 2.32 (m,lH), 3.14 (dd, IH), 3.33
(dd, IH), 3.72 (m, IH).
Mass Spectrum m/e = 171 (M+l).
EXAMPLE 34
1 (RV6(S -4-Amino-3-thia-5-aza-cis-bicyclo(4.4.0Vdec-4-ene (L- 766.423
The title compound was prepared from l(S)-2(R)-l-amino- 2-hydroxymethyl-cyclohexane by the method of Example 26 steps C and D. The compounds of Examples 35-38 were synthssized by the method of Example 26 steps C and D starting with the appropriate aminoalcohol.
H NMR (CD3OD) δ: 1.3-2.0 (m, 9 H), 2.85 (dd, IH), 3.12 (dd, IH), 3.45 (m, IH).
Mass Spectrum m/e = 171 (M+l).
EXAMPLE 35
2-Amino-4-methyl-5.6-dihydro-4H- 1.3-thiazine hydrochloride
lH NMR (CD3OD) δ: 1.32 (d, 3H), 1.83 (m, IH), 2.3 (m, IH), 3.25 (m, 2H), 3.7 (m, IH).
Mass Spectrum m/e = 131 (M+l).
EXAMPLE 36
2-Amino-4-phenyl-5.6-dihvdro-4H- 1.3-thiazine hydrochloride
lH NMR (CD3OD) δ: 2.2-2.5 (m, 2H), 3.1 (m, IH), 3.34 (m, IH), 4.86 (dd, IH), 7.3-7.5 (m, 5H).
Mass Spectrum m/e = 193 (M+l).
EXAMPLE 37
2- Amino-5-phenyl-5.6-dihvdro-4H- 1.3-thiazine hydrochloride
lH NMR (CD3OD) δ: 2.9-3.6 (m, 5H), 7.2-7.5 (m, 5H).
Mass Spectrum m/e = 193 (M+l).
EXAMPLE 38 2- Amino-5-methyl-5.6-dihydro-4H- 1.3-thiazine hydrochloride
Mass Spectrum m/e = 131 (M+l).
EXAMPLE 39
2-Amino-6-methyl-5.6-dihvdro-4H- 1 ,3-thiazine hydrochloride
H NMR (CD3OD) δ: 1.43 (d, 3H), 1.82 (m, IH), 2.3 (m, IH), 3.45 (m, 2H), 3.65 (m, 2H).
Mass Spectrum m/e = 131 (M+l).
EXAMPLE 40
2- Amino-6.6-dimethyl-5.6-dihydro-4H- 1 ,3-thiazine hydrochloride
lH NMR (CD3OD) δ: 1.52 (s, 6H), 2.06 (dd, 2H), 3.62 (dd, 2H).
Mass Spectrum m/e = 131 (M+l).
EXAMPLE 41
2- Amino-6-phenyl-5.6-dihydro-4H- 1.3-thiazine hydrochloride
Mass Spectrum m/e = 193 (M+l).

Claims

WHAT IS CLAIMED IS:
1. A compound of Formula I
Figure imgf000054_0001
I
or a pharmaceutically acceptable salt thereof wherein: side a or side b has a double bond, n is O, 1, 2, 3 or 4 X is selected from O, S and NH,
Rl, R2 and R3 are each independently selected from the group consisting of
(a) hydrogen,
(b) Ci-i2alkoxy, (c) C 1.12alkylS(0)k wherein k is 0, 1 or 2,
(d) mono C l - 12alkylamino,
(e) (di-C 1 - 12alkyl)amino, (0 Ci-i2alkylcarbonyl, (g) CM2alkyl, (h) C2-12alkenyl,
(i) C2-12alkynyl, (j) C5-I Ocycloalkyl,
(k) hetero C5- 1 Ocycloalkyl, wherein the hetero C5- 1 ocycloalkyl optionally contains 1 or 2 heteroatoms selected from S, O and N,
(1) aryl, selected from phenyl or naphthyl, (m) heteroaryl, wherein heteroaryl is selected from the group consisting of:
( 1 ) benzimidazolyl, (2) benzofuranyl,
(3) benzooxazolyl,
(4) furanyl,
(5) imidazolyl,
(6) indolyl,
(7) isooxazolyl,
(8) isothiazolyl,
(9) oxadiazolyl,
(10) oxazolyl,
(I D pyrazinyl,
(12) pyrazolyl,
(13) pyridyl,
(14) pyrimidyl,
(15) pyrrolyl,
(17) isoquinolyl,
(18) tetrazolyl,
(19) thiadiazolyl,
(20) thiazolyl,
(21) thienyl, and
(22) triazolyl,
(n) amino,
(o) oxo,
(P) C(0)OH,
(q) C(0)OR6, R6 is selected from hydrogen, phenyl, cyclohexyl or Ci-6alkyl, each of (b) to (m) being optionally mono or di- substituted the substituents being independently selected from
(1) hydroxy,
(2) carboxy,
(3) -NR6R7, where R7 is selected from hydrogen, phenyl, cyclohexyl or Ci-6alkyl,
(4) -OR6,
(5) -C02R6,
(6) -S(0)kR6, (7) halo selected from F, Cl, Br and I,
(8) -C(=NR6)-NHR7, (9)-S-C(=NR6)-NHR7, provided that when Rl, R2 or R3 is hydroxy, amino, mono Cl-4alkylamino or (di-Ci-4alkyl)amino, said Rl, R2 or R3 must not reside alpha to a hetero atom of the ring on which it resides, or when two members of the group Rl, R2 and R3 reside on the same carbon atom of Formula I, or two of the group Rl, R2 and R3 reside on adjacent atoms of Formula I, said two members may optionally be joined, such that together with the carbon atom to which they are attached there is formed a samrated or unsaturated monocyclic ring of 5, 6 or 7 atoms, said monocyclic ring optionally containing up to three hetero atoms selected from N, O or S, or when a member of the group Rl , R2 and R3 resides on an atom adjacent to the N on which R4 resides, said member may optionally be joined with R4, such that together with the N on which R4 resides and the carbon on which said member resides there is formed a samrated or unsaturated monocyclic heterocycle of 5, 6 or 7 atoms, said monocycle optionally containing up to three hetero atoms selected from N, O or S, R5 are each independently selected from the group consisting of (a) hydrogen,
(b) linear and branched Ci-i2alkyl, optionally mono or di- substituted, the substituents being independently selected from
(1) hydroxy, (2) carboxy,
(3) -NR6R7,
(4) -OR6,
(5) -C02R6,
(6) -S(0)kR6, (7) halo selected from F, Cl, Br and I,
(8) phenyl, optionally mono or di-substituted with hydroxy, halo, Ci-4alkyl, or Ci-4alkoxy,
(c) -CONR8R9, where R8 and R9 are each independently hydrogen, phenyl, cyclohexyl or Ci-6alkyl, said Cl-6alkyl optionally substituted by
(1) hydroxy,
(2) amino,
(3) carboxy, (4) -NRioRl 1 , wherein RlO and R 11 are each independently H, Cl-6alkyl, phenyl or benzyl,
(5) -OR10,
(6) -CO2R10,
(7) -S(O)mRl0> where m is 0, 1 or 2, (8) halo selected from F, Cl, Br and I,
(9) optionally substituted aryl wherein aryl and aryl substituents are as defined above,
(10) optionally substituted heteroaryl wherein heteroaryl and heteroaryl substituents are as defined above, (11) optionally substituted C5- 1 Ocycloalkyl wherein cycloalkyl and cycloalkyl substituents are as defined above, (12) optionally substituted hetero C5-I Ocycloalkyl wherein hetero cycloalkyl and hetero cycloalkyl substituents are as defined above,
(d) -CSNR8R9,
(e) -COR9,
(f) -CO2R9,
(g) -CSR9, (h) phenyl,
(i) cyclohexyl, provided that R4 is present only when side a is a single bond and side b is a double bond, and further provided that when n is 0 or 1, X is S and Rl , R2, R3, and R4 are hydrogen, then R5 is other than hydrogen or methyl. 2. A compound according to claim 1 wherein n is O, 1,
2, 3 or 4, X is selected from O, S and NH, Rl, R2 and R3 are each independently selected from the group consisting of
(a) hydrogen,
(b) Ci-6alkoxy,
(c) Cl-6alkylamino, (d) Cl-6alkylcarbonyl,
(e) Ci-6alkyl,
(f) C2-6alkenyl,
(g) C2-6alkynyl,
(h) C5, C6 or C7cycloalkyl, (i) hetero C5, C6 or C7cycloalkyl,wherein the hetero C5, C6 or
C7cycloalkyl optionally contains 1 or 2 heteroatoms selected from S, O and N, (j) aryl, selected from phenyl or naphthyl, (k) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) benzimidazolyl,
(2) benzofuranyl,
(3) benzooxazolyl,
(4) furanyl, (5) imidazolyl,
(6) indolyl,
(7) isooxazolyl,
(8) isothiazolyl,
(9) oxadiazolyl, (10) oxazolyl,
(11) pyrazinyl,
(12) pyrazolyl,
(13) pyridyl,
(14) pyrimidyl, (15) pyrrolyl,
(16) quinolyl,
(17) tetrazolyl,
(18) thiadiazolyl, (19) thiazolyl,
(20) thienyl, and
(21) triazolyl, each of (b) to (k) being optionally mono or di- substituted the substituents being independently selected from (1) hydroxy,
(2) carboxy,
(3) -NR6R7, where Rό and R7 are selected from hydrogen, phenyl, cyclohexyl or Ci-6alkyl,
(4) -OR6, (5) -C02R6,
(6) -S(0)kR6,
(7) halo selected from F, Cl, Br and I,
(8) -C(=NR6)-NHR7, (9)-S-C(=NR6)-NHR7, or when two members of the group Rl, R2 and R3 reside on the same carbon atom of Formula I, or two of the group Rl, R2 and R3 reside on adjacent atoms of Formula I, said two members may optionally be joined, such that together with the carbon atom to which they are attached there is formed a saturated or unsaturated monocyclic ring of 5, 6 or 7 atoms, said monocyclic ring optionally containing up to three hetero atoms selected from N, O or S, or when a member of the group Rl, R2 and R3 resides on an atom adjacent to the N on which R4 resides, said member may optionally be joined with R4, such that together with the N on which R4 resides and the carbon on which said member resides there is formed a samrated or unsaturated monocyclic heterocycle of 5, 6 or 7 atoms, said monocycle optionally containing up to three hetero atoms selected from N, O or S, R5 are each independently selected from the group consisting of
(a) hydrogen, (b) linear and branched C l -6alkyl, optionally mono or di- substituted, the substituents being independently selected from
(1) hydroxy,
(2) carboxy, (3) -NR6R7,
(4) -OR6,
(5) -C02R6,
(6) -S(0)kR6, where k is 0, 1 or 2,
(7) halo selected from F, Cl, Br and I, (c) -CONR8R9, where R8 and R9 are each independently hydrogen, phenyl, cyclohexyl or Cl-4alkyl, said Cl-4alkyl optionally substimted by
(1) hydroxy,
(2) amino, (3) carboxy,
(4) -NRioRl 1, wherein Rio and Rl \ are each independently H, Cl-4alkyl, phenyl or benzyl,
(5) -OR10, (6) -CO2Ri0, (7) -S(O)mRl0» where m is 0, 1 or 2,
(8) halo selected from F, Cl, Br and I,
(9) optionally substimted aryl wherein aryl andaryl substituents are as defined above,
(10) optionally substimted heteroaryl wherein heteroaryl and heteroaryl substituents are as defined above,
(11) optionally substimted C5, C6 or C7cycloalkyl wherein cycloalkyl and cycloalkyl substituents are as defined above, (12) optionally substituted hetero C5, C6 or C7cycloalkyl wherein hetero cycloalkyl and hetero cycloalkyl substituents are as defined above, (d) -CSNR8R9, (e) -COR9,
(f) -CO2R9,
(g) -CSR9, (h) phenyl,
(i) cyclohexyl, such that R4 is present only when side a is a single bond and side b is a double bond.
3. A compound according to claim 2 wherein n is O, 1, 2, 3 or 4, X is selected from O, S and NH,
Rl, R2 and R3 are each independently selected from the group consisting of
(a) hydrogen,
(b) Ci_6alkoxy, (c) Ci-6alkylamino,
(d) Ci-6alkylcarbonyl,
(e) Ci-6alkyl,
(f) C2-6alkenyl,
(g) C5, C6 or C7cycloalkyl, (h) hetero C5 or C6 cycloalkyl, wherein the hetero C5 or C6 cycloalkyl optionally contains 1 heteroatom selected from S, O and N, (i) aryl, selected from phenyl or naphthyl, (j) heteroaryl, wherein heteroaryl is selected from the group consisting of:
(1) furanyl,
(2) pyrazinyl,
(3) pyrazolyl,
(4) pyridyl, (5) pyrimidyl,
(6) thiazolyl,
(7) thienyl, and
(8) triazolyl, each of (b) to (j) being optionally mono or di- substimted the substituents being independently selected from
(1) hydroxy,
(2) carboxy,
(3) -NR6R7, wherein R6 and R7 are each independently hydrogen or C 1 -4alkyl,
(4) -OR6,
(5) -C02R6,
(6) -S(0)kR6, where k is 0, 1 or 2,
(7) halo selected from F, Cl, Br and I, (8) -C(=NR6)-NHR7,
(9)-S-C(=NR6)-NHR7, or when two members of the group Rl, R2 and R3 reside on the same carbon atom of Formula I, or two of the group Rl , R2 and R3 reside on adjacent atoms of Formula I, said two members may optionally be joined, such that together with the carbon atom to which they are attached there is formed a samrated or unsaturated monocyclic ring of 5, 6 or 7 atoms, said monocyclic ring optionally containing up to three hetero atoms selected from N, O or S, or when a member of the group Rl , R2 and R3 resides on an atom adjacent to the N on which R4 resides, said member may optionally be joined with R4, such that together with the N on which R4 resides and the carbon on which said member resides there is formed a samrated or unsaturated monocyclic heterocycle of 5, 6 or 7 atoms, said monocycle optionally containing up to three hetero atoms selected from N, O or S, R5 are each independently selected from the group consisting of (a) hydrogen, (b) linear and branched C 1 -6alkyl, optionally mono or di- substituted, the substituents being independently selected from
(1) hydroxy, 5 (2) carboxy,
(3) -NR6R7,
(4) -OR6,
(5) -C02R6,
(6) -S(0)kR6, ι o (7) halo selected from F, Cl, Br and I,
(c) -CONR8R9, where R and R9 are each independently hydrogen, phenyl, cyclohexyl or Cl-4alkyl, said Cl-4alkyl optionally substimted by
(I) hydroxy, 15 (2) amino,
(3) carboxy,
(4) -NRioRl 1, wherein Rio and Rl 1 are each independently H, Cl-4alkyl, phenyl or benzyl,
(5) -ORlO, 20 (6) -CO2R10,
(7) -S(O)mRl0, where m is 1 or 2,
(8) halo selected from F, Cl, Br and I,
(9) optionally substimted aryl wherein aryl and aryl substituents are as defined above, 25 (10) optionally substimted heteroaryl wherein heteroaryl and heteroaryl substituents are as defined above,
(II) optionally substituted C5 or C6 cycloalkyl wherein cycloalkyl and cycloalkyl substituents are as defined above, 0 (12) optionally substituted hetero C5 or C cycloalkyl wherein hetero cycloalkyl and hetero cycloalkyl substituents are as defined above,
(d) -CSNR8R9,
(e) -COR9, (f) -C02R9,
(g) -CSR9, (h) phenyl, (i) cyclohexyl, such that R4 is present only when side a is a single bond and side b is a double bond.
4. A compound according to Claim 3 wherein n is O, 1, 2 or 3, X is selected from O, S and NH,
Rl, R2 and R3 are each independently selected from the group consisting of
(a) hydrogen,
(b) Cι_4alkoxy, (c) Ci-4alkylamino,
(d) Ci-4alkylcarbonyl,
(e) linear and branched Ci-4alkyl, each of (b) to (e) being optionally mono or di- substituted the substituents being independently selected from (1) hydroxy,
(2) carboxy,
(3) -NR6R7, wherein R6 and R7 are each independently hydrogen or C 1-3 alkyl,
(4) -OR6, (5) -C02R6,
(6) -S(0)kR6, where k is 0, 1 or 2,
(7) halo selected from F, Cl, Br and I, or when two members of the group Rl, R2 and R3 reside on the same carbon atom of Formula I, or two of the group Rl , R2 and R3 reside on adjacent atoms of Formula I, said two members may optionally be joined, such that together with the carbon atom to which they are attached there is formed a samrated or unsaturated monocyclic ring of 5, 6 or 7 atoms, said monocyclic ring optionally containing up to three hetero atoms selected from N, O or S, or when a member of the group Rl, R2 and R3 resides on an atom adjacent to the N on which R4 resides, said member may optionally be joined with R4, such that together with the N on which R4 resides and the carbon on which said member resides there is formed a samrated or unsaturated monocyclic heterocycle of 5, 6 or 7 atoms, said monocycle optionally containing up to three hetero atoms selected from N, O or S,
R4 and R5 are each independently selected from the group consisting of
(a) hydrogen,
(b) -CONR8R9, where R8 and R9 are each independently hydrogen or Cl-3alkyl, said Ci-3alkyl optionally substimted by
(1) hydroxy,
(2) amino,
(3) carboxy,
(4) -NRioRl 1, wherein Rio and Rl 1 are each independently H or C 1 -3alkyl,
(5) -ORlO,
(6) -CO2R10,
(7) -S(O)mRi0, where m is 0, 1 or 2,
(8) halo selected from F, Cl, Br and I, (c) -CSNR8R9,
(d) -COR9,
(e) -C02R9,
(f) -CSR9,
(g) -Ci-4alkyl.
5. A compound according to Claim 4 wherein
n is O, 1, 2 or 3
X is selected from O, S and NH, Rl, R2 and R3 are each independently selected from the group consisting of
(a) hydrogen,
(b) Cl-4alkoxy, (c) Cl-4alkylamino,
(d) Cl-4alkylcarbonyl,
(e) linear and branched C l -4alkyl, each of (b) to (e) being optionally mono or di- substimted the substituents being independently selected from (1) hydroxy,
(2) carboxy,
(3) -NR6R7, wherein R6 and R7 are each independently hydrogen or C l -3alkyl,
(4) -OR6, (5) -C02R6,
(6) -S(0)kR6, where k is 0, 1 or 2,
(7) halo selected from F, Cl, Br and I, R4 is selected from the group consisting of
(a) hydrogen, (b) -CONHR9, where R9 is hydrogen or Ci-3alkyl, said Cl-3alkyl optionally substimted by
(1) hydroxy,
(2) amino,
(3) carboxy, (4) -NRioRl 1, wherein Rio and Rl 1 are each independentiy C 1 -3 alkyl,
(5) -OR10,
Figure imgf000066_0001
(7) -S(O)mRl0, where m is 1 or 2, (8) halo selected from F, Cl, Br and I,
(c) -CSNHR9;
(d) -Ci-4alkyl.
R5 is selected from the group consisting of (a) hydrogen, (b) -CONHR9,
(c) -CSNR8R9.
(d) -Ci-4alkyl.
6. A compound according to Claim 4 of the formula
Figure imgf000067_0001
or
or tautomers thereof wherein n is 0, 1 or 2.
7. A compound according to Claim 6 wherein n is 0, 1 or 2,
X is selected from O, S and NH, Rl and R2 are each independently selected from the group consisting of
(a) hydrogen,
(b) linear and branched C 1 -4alkyl, each of (a) and (b) being optionally mono or di- substimted the substituents being independently selected from
(1) carboxy,
(2) -NHR7, wherein R6 and R7 are each independently hydrogen or Cl-3alkyl,
(3) -OR6,
(4) -C02R6,
(5) -S(0)kR6, where k is 0, 1 or 2, R4 is selected from the group consisting of
(a) hydrogen,
(b) -CONHR9, where R9 is hydrogen or C 1 -3alkyl, said C 1 - 3alkyl optionally substimted by
(1) hydroxy,
(2) amino, (3) carboxy,
(4) -NRloRl 1, wherein Rio and Rl l are each independently Ci-3alkyl, (5) -ORiO,
(6) -CO2R10,
(7) -S(O)mRl0, where m is 0, 1 or 2, (9) halo selected from F, Cl, Br and I,
(c) -CSNHR9; (d) Ci-3alkyl;
R5 are each independently selected from the group consisting of
(a) hydrogen,
(b) -CONHR9,
(c) -CSNR8R9, (d) Ci-3alkyl.
8. A compound according to Claim 7 of the formulae
Figure imgf000068_0001
9. A compound according to Claim 8 wherein X is selected from S and NH,
Rl is selected from the group consisting of
(a) hydrogen,
(b) linear and branched C 1 -4alkyl, said C 1 -4alkyl being optionally mono or di- substituted the substiments being independently selected from
(1) carboxy,
(2) -NR6R7, wherein R and R7 are each independently hydrogen or Cl-3alkyl,
(3) -OR6, (4) -C02R6,
(5) -S(0)kR6, where k is 0, 1 or 2, R4 is selected from the group consisting of
(a) hydrogen, (b) -CONHR9, where R9 is hydrogen or C 1 -4alkyl, said C l -
4alkyl optionally substituted by
(1) hydroxy,
(2) amino,
(3) carboxy, (4) -NRloRl 1 , wherein RlO and R 11 are each independently Cl-3alkyl,
(5) -OR10,
(6) -CO2R10, (7) -S(O)mRl0, where m is 0, 1 or 2,
(8) halo selected from F, Cl, Br and I,
(c) -CSNHR9;
(d) Cl-3alkyl;
R5 is selected from the group consisting of (a) hydrogen,
(b) -CONHR9,
(c) -CSNR8R9,
(d) Cl-3alkyl.
10. Acompound according to Claim 9 wherein
X is selected from S and NH, Rl is selected from the group consisting of
(a) hydrogen,
(b) linear and branched C 1 -4alkyl, said C 1 -4alkyl being optionally mono or di- substituted the substiments being independently selected from
(1) carboxy,
(2) -NHR7, wherein R6 and R7 are each independently hydrogen or Ci-3alkyl, (3) -C02R6, and (4) -S(0)kR6, where k is 0, 1 or 2, R4 is selected from the group consisting of (a) hydrogen, (b) Ci-3alkyl;
R5 is selected from the group consisting of
(a) hydrogen,
(b) -CONHR9, where R9 is hydrogen or Cl-4alkyl, said Ci-4alkyl optionally substituted by (1) hydroxy,
(2) amino,
(3) carboxy,
(4) -NRloRl 1, wherein RlO and Rl 1 are each independently Ci-3alkyl,
(5) -ORlO,
(6) -CO2R10, (7) -SRio, and
(8) -S(O)mRl0> where m is 1 or 2, (9) halo selected from F, Cl, Br and I,
(c) -CSNR8R9,
(d) Ci-3alkyl.
11. A compound of Claim 1 selected from (a) 2-Amino-5,6-dihydro-3H-l,3-thiazine;
(b) 2-Methylamino-5,6-dihydro-3H- 1 ,3-thiazine;
(c) 2-Ethylamino-5,6-dihydro-3H- 1 ,3-thiazine;
(d) 2-Propylamino-5,6-dihydro-3H- 1 ,3-thiazine;
(e) 2-(2-Methylethyl)amino-5,6-dihydro-3H- 1 ,3-thiazine; (f) 2-Butylamino-5,6-dihydro-3H-l,3-thiazine;
(g) 2-(2,2-Dimethylethyl)amino-5,6-dihydro-3H- 1 ,3- thiazine; (h) 2-(Cyclohexyl)amino-5,6-dihydro-3H- 1 ,3-thiazine; (i) 2-Phenylamino-5,6-dihydro-3H- 1 ,3-thiazine; (j) 2-(3-Dimethylaminpropyl)amino-5,6-dihydro-3H- 1 ,3- thiazine; (k) 2-(2-Dimethylaminoethyl)amino-5,6-dihydro-3H- 1 ,3- thiazine; (1) 2-(3-Diethylaminopropylamino-thiocarbonyl-amino)-
5,6-dihydro-3H- 1 ,3-thiazine; (m) 2-(3-Dimethylaminopropylamino-thiocarbonyl- amino)-5,6-dihydro-3H-l,3-thiazine; (n) 2-(2-Dimethylaminoethylamino-thiocarbonyl-amino)- 5,6-dihydro-3H-l,3-thiazine;
(o) 2-(3-Diethylaminopropyl)ethylamino-thiocarbonyl- amino)-5,6-dihydro-3H- 1 ,3-thiazine; (p) 2-(2-Dimethylaminoethyl)propylamino-thiocarbonyl- amino)-5,6-dihydro-3H- 1 ,3-thiazine; (q) 2-(2-Diethylaminoethyl)propylamino-thiocarbonyl- amino)-5 ,6-dihydro-3H- 1 ,3-thiazine; (r) dihydro-3H-l,3-thiazine; (s) 2-Benzoylamino-4H-3, 1 -benzothiazine; (t) 2-Amino-4H-3,l-benzothiazine; (u) 5-(2-Thiazolinyl)amino-norvaline hydrochloride;
(v) 5-(S)-2-Imino-3-thia-l-aza-bicyclo(3.3.0)octane; (w) 2-Amino-4-iodomethyl-thiazoline; (x) 2-Amino-4-hydroxymethyl-thiazoline; and (y) S-((2-amino-thiazolino)methyl)isothiourea, or a pharmaceutically acceptable salt thereof.
12. A compound according to Claim 1 selected from the group consisting of
(a) 2-Amino-cis-5,6-dimethyl-5,6-dihydro-4H- 1 ,3- thiazine, methanesulfonic acid salt,
(b) 2-Amino-trans-5,6-dimethyl-5,6-dihydro-4H- 1 ,3- thiazine hydrobromide,
(c) 3-Amino-2-thia-4-aza-cis-bicyclo(4,4,0)-dec-3-ene hydrochloride, (d) 3-Amino-2-thia-4-aza-cis-bicyclo(4,3,0)-non-3-ene, methane sulfonic acid salt,
(e) 2-Amino-trans-4,5-dimethyl-5,6-dihydro-4H- 1 ,3- thiazine, (f) 2-Amino-cis-4,5-dimethyl-5,6-dihydro-4H-l,3- thiazine, methane sulfonic acid salt
(g) 4-Amino-3-thia-5-aza-trans-bicyclo(4,4,0)-dec-4-ene, methane sulfonic acid salt,
(h) 1 (S)-6(R)-4-Amino-3-thia-5-aza-cis-bicyclo(4,4,0)- Q dec-4-ene hydrochloride,
(i) 1 (R)-6(S)-4-Amino-3-thia-5-aza-cis-bicyclo(4,4,0)- dec-4-ene,
(j) 2-Amino-4-methyl-5,6-dihydro-4H- 1 ,3-thiazine hydrochloride, 5 (k) 2-Amino-4-phenyl-5,6-dihydro-4H-l,3-thiazine hydrochloride,
(1) 2-Amino-5-phenyl-5,6-dihydro-4H- 1 ,3-thiazine hydrochloride,
(m) 2-Amino-5-methyl-5,6-dihydro-4H- 1 ,3-thiazine 0 hydrochloride,
(n) 2-Amino-6-methyl-5,6-dihydro-4H- 1 ,3-thiazine hydrochloride,
(m) 2-Amino-6,6-dimethyl-5,6-dihydro-4H- 1 ,3-thiazine hydrochloride, and 5 (n) Amino-6-phenyl-5,6-dihydro-4H-l,3-thiazine hydrochloride.
13. A pharmaceutical composition for treating a nitric oxide synthase mediated disease comprising a pharmaceutical carrier and 0 a non-toxic effective amount of the compound of Claim 1.
14. A method for inhibiting the activity of nitric oxide synthases comprising administering to a subject suffering from a nitric oxide synthase mediated disease, a non-toxic therapeutically effective amount of the compound of Claim 1.
PCT/US1995/014512 1994-11-15 1995-11-13 Substituted heterocycles as inhibitors of nitric oxide synthase WO1996014842A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU41496/96A AU4149696A (en) 1994-11-15 1995-11-13 Substituted heterocycles as inhibitors of nitric oxide synthase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33961894A 1994-11-15 1994-11-15
US339,618 1994-11-15

Publications (1)

Publication Number Publication Date
WO1996014842A1 true WO1996014842A1 (en) 1996-05-23

Family

ID=23329864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/014512 WO1996014842A1 (en) 1994-11-15 1995-11-13 Substituted heterocycles as inhibitors of nitric oxide synthase

Country Status (2)

Country Link
AU (1) AU4149696A (en)
WO (1) WO1996014842A1 (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19530870A1 (en) * 1994-12-14 1996-06-20 Japan Tobacco Inc New 2-amino-1,3-thiazine and -thiazepine derivs.
EP0870763A1 (en) * 1997-04-10 1998-10-14 Ono Pharmaceutical Co., Ltd. Condensed piperidine derivatives used as a nitrogen monoxide synthase inhibitors
US5854234A (en) * 1993-10-21 1998-12-29 G. D. Searle & Co. Amidino dervatives useful as nitric oxide synthase inhibitors
US5872124A (en) * 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
US5883251A (en) * 1995-04-20 1999-03-16 G. D. Searle & Co. Azepine derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US5958958A (en) * 1997-07-22 1999-09-28 G.D. Searle & Co. 1,2,4-oxa diazolino and 1,24-oxa diazolidion heterocycles as useful nitric oxide synthase inhibitors
WO2000064904A1 (en) * 1999-04-28 2000-11-02 Astrazeneca Ab 5,7-bicyclic amidine derivatives useful as nitric oxide synthase inhibitors
WO2001094325A1 (en) * 2000-06-09 2001-12-13 Aventis Pharma S.A. 2-aminothiazoline derivatives and their use as no-synthase inhibitors
WO2001093867A1 (en) * 2000-06-09 2001-12-13 Aventis Pharma S.A. 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
US6353006B1 (en) 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
EP1004317A4 (en) * 1997-08-12 2002-06-05 Chugai Pharmaceutical Co Ltd USE OF SELECTIVE iNOS INHIBITORS FOR TREATING BONE RESORPTION-ASSOCIATED DISEASES
US6420566B2 (en) 2000-06-09 2002-07-16 Aventis Pharma S.A. Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6433019B1 (en) 1998-01-30 2002-08-13 Sumitomo Pharmaceuticals Company, Limited Neurotrophic factor secretion promoters
US6451821B1 (en) 2000-06-09 2002-09-17 Aventis Pharma S.A. Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase
US6489323B1 (en) 1998-06-10 2002-12-03 G.D. Searle & Co. Heterobicyclic and tricyclic nitric oxide synthase inhibitors
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
WO2003022309A1 (en) * 2001-09-10 2003-03-20 Ono Pharmaceutical Co., Ltd. Remedies for allergic diseases
WO2003040115A1 (en) * 2001-11-09 2003-05-15 Aventis Pharma S.A. 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
WO2003040142A1 (en) * 2001-11-09 2003-05-15 Aventis Pharma S.A. 2-amino-4-heteroarylethyl thiazoline derivatives and their use an inhibitors of inducible no-synthase
FR2832152A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes
FR2832150A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-4-(pyridylmethyl) thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating of Parkinson's disease, cerebral disorders, migraines, depression, diabetes
FR2832151A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-4-(heteroarylethyl) thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes
WO2003075922A1 (en) * 2002-03-14 2003-09-18 Dainippon Pharmaceutical Co., Ltd. Nitrogen monoxide synthase inhibitors
WO2003039446A3 (en) * 2001-11-09 2003-11-27 Aventis Pharma Sa Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
WO2007049532A1 (en) 2005-10-25 2007-05-03 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
WO2008133273A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Pharmaceutical composition for treatment of alzheimer's disease
WO2008133274A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
WO2009151098A1 (en) 2008-06-13 2009-12-17 塩野義製薬株式会社 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING β-SECRETASE-INHIBITING ACTIVITY
US7648983B2 (en) 2008-05-02 2010-01-19 Eli Lilly And Company BACE inhibitors
WO2010041964A1 (en) * 2008-10-09 2010-04-15 Victoria Link Limited Methods for the preparation of alkenylamines, cyclic carbamates or dithiocarbamates, and aminoalcohols or aminothiols
TWI423970B (en) * 2008-01-18 2014-01-21 Eisai R&D Man Co Ltd Fused aminodihydrothiazine derivatives
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
JP2016503785A (en) * 2012-12-19 2016-02-08 ファイザー・インク Carbocyclic and heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds
JP2016507551A (en) * 2013-02-13 2016-03-10 ファイザー・インク Heteroaryl-substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds
JP2016507580A (en) * 2013-02-15 2016-03-10 ファイザー・インク Substituted phenylhexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
WO2019177142A1 (en) * 2018-03-16 2019-09-19 脳科学香料株式会社 Prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation, cell protection agent for transplantation, and bio-preservation agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012165A2 (en) * 1992-11-27 1994-06-09 The Wellcome Foundation Limited Enzyme inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012165A2 (en) * 1992-11-27 1994-06-09 The Wellcome Foundation Limited Enzyme inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 116, issued 1992, MAZUREK et al., "Theroretical Studies on Tautomerism of Clonidine in Vacuum and in Water Medium", page 773, Abstract 58395n; & THEOCHEM, 82(1-2), pages 23-28. *

Cited By (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448286B1 (en) 1993-10-21 2002-09-10 G.D. Searle & Co. Imino pyrrolidine derivatives useful as nitric oxide synthase inhibitors
US5854234A (en) * 1993-10-21 1998-12-29 G. D. Searle & Co. Amidino dervatives useful as nitric oxide synthase inhibitors
US6071906A (en) * 1993-10-21 2000-06-06 G. D. Searle & Co. Imidino piperidine derivatives useful as nitric oxide synthase inhibitors
US6046211A (en) * 1993-10-21 2000-04-04 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
DE19530870A1 (en) * 1994-12-14 1996-06-20 Japan Tobacco Inc New 2-amino-1,3-thiazine and -thiazepine derivs.
US6043261A (en) * 1995-04-20 2000-03-28 G. D. Searle & Co. Pyrrolodino imidines useful as nitric oxide synthase inhibitors
US5883251A (en) * 1995-04-20 1999-03-16 G. D. Searle & Co. Azepine derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US5872124A (en) * 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
US6849739B2 (en) 1997-02-19 2005-02-01 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6864263B2 (en) 1997-02-19 2005-03-08 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6887865B2 (en) 1997-02-19 2005-05-03 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6841674B2 (en) 1997-02-19 2005-01-11 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6864368B2 (en) 1997-02-19 2005-03-08 Berlax Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6747031B2 (en) 1997-02-19 2004-06-08 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6841673B2 (en) 1997-02-19 2005-01-11 Berlex Laboratories, Inc. N-heterocyclic derivatives as nos inhibitors
US6670473B2 (en) 1997-02-19 2003-12-30 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6846829B2 (en) 1997-02-19 2005-01-25 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6110930A (en) * 1997-04-10 2000-08-29 Ono Pharmaceutical Co., Ltd. Condensed piperidine compound
US6228866B1 (en) 1997-04-10 2001-05-08 Ono Pharmaceutical Co., Ltd. Condensed piperidine compound
EP0870763A1 (en) * 1997-04-10 1998-10-14 Ono Pharmaceutical Co., Ltd. Condensed piperidine derivatives used as a nitrogen monoxide synthase inhibitors
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
US6136829A (en) * 1997-07-22 2000-10-24 G.D. Searle & Co. Oxathiadiazole derivatives usful as iNOS inhibitors
US5958958A (en) * 1997-07-22 1999-09-28 G.D. Searle & Co. 1,2,4-oxa diazolino and 1,24-oxa diazolidion heterocycles as useful nitric oxide synthase inhibitors
EP1004317A4 (en) * 1997-08-12 2002-06-05 Chugai Pharmaceutical Co Ltd USE OF SELECTIVE iNOS INHIBITORS FOR TREATING BONE RESORPTION-ASSOCIATED DISEASES
US6433019B1 (en) 1998-01-30 2002-08-13 Sumitomo Pharmaceuticals Company, Limited Neurotrophic factor secretion promoters
US6489323B1 (en) 1998-06-10 2002-12-03 G.D. Searle & Co. Heterobicyclic and tricyclic nitric oxide synthase inhibitors
US6353006B1 (en) 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
WO2000064904A1 (en) * 1999-04-28 2000-11-02 Astrazeneca Ab 5,7-bicyclic amidine derivatives useful as nitric oxide synthase inhibitors
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US6699895B2 (en) 2000-06-09 2004-03-02 Aventis Pharma S.A. 2-aminothiazoline derivatives and process for preparing the same
US6451821B1 (en) 2000-06-09 2002-09-17 Aventis Pharma S.A. Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase
US6420566B2 (en) 2000-06-09 2002-07-16 Aventis Pharma S.A. Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof
FR2810036A1 (en) * 2000-06-09 2001-12-14 Aventis Pharma Sa Compositions containing new or known 4-substituted 4,5-dihydro-thiazol-2-ylamines, as inducible nitrogen monoxide synthase inhibitors useful e.g. for treating neurodegenerative or inflammatory diseases
FR2810037A1 (en) * 2000-06-09 2001-12-14 Aventis Pharma Sa Inducible nitrogen monoxide synthase inhibitors comprising new or known 4- and/or 5-substituted 4,5-dihydro-thiazol-2-ylamine compounds, useful e.g. for treating neurodegenerative or inflammatory diseases
WO2001093867A1 (en) * 2000-06-09 2001-12-13 Aventis Pharma S.A. 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors
WO2001094325A1 (en) * 2000-06-09 2001-12-13 Aventis Pharma S.A. 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU2001266123B2 (en) * 2000-06-09 2007-01-25 Aventis Pharma S.A. 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
EP1426060A4 (en) * 2001-09-10 2004-12-01 Ono Pharmaceutical Co Remedies for allergic diseases
WO2003022309A1 (en) * 2001-09-10 2003-03-20 Ono Pharmaceutical Co., Ltd. Remedies for allergic diseases
US6872740B2 (en) 2001-11-09 2005-03-29 Aventis Pharma S.A. Use of 2-amino-4-heteroarylethyl-thiazoline derivatives as inhibitors of inducible no-synthase
WO2003040115A1 (en) * 2001-11-09 2003-05-15 Aventis Pharma S.A. 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
US6699867B2 (en) 2001-11-09 2004-03-02 Aventis Pharma S.A. Use of 2-amino-thiazoline derivatives as inhibitors of inducible NO-synthase
WO2003039446A3 (en) * 2001-11-09 2003-11-27 Aventis Pharma Sa Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
US6762196B2 (en) 2001-11-09 2004-07-13 Aventis Pharma S. A. Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
FR2832151A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-4-(heteroarylethyl) thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes
FR2832150A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-4-(pyridylmethyl) thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating of Parkinson's disease, cerebral disorders, migraines, depression, diabetes
FR2832152A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes
WO2003040142A1 (en) * 2001-11-09 2003-05-15 Aventis Pharma S.A. 2-amino-4-heteroarylethyl thiazoline derivatives and their use an inhibitors of inducible no-synthase
US6953796B2 (en) 2001-11-09 2005-10-11 Aventis Pharma S.A. Use of 2-amino-thiazoline derivatives as inhibitors of inducible No-synthase
US7227022B2 (en) 2001-11-09 2007-06-05 Aventis Pharma Sa Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase
WO2003075922A1 (en) * 2002-03-14 2003-09-18 Dainippon Pharmaceutical Co., Ltd. Nitrogen monoxide synthase inhibitors
US7202263B2 (en) 2002-04-30 2007-04-10 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
WO2007049532A1 (en) 2005-10-25 2007-05-03 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
US9029358B2 (en) 2005-10-25 2015-05-12 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8633188B2 (en) 2005-10-25 2014-01-21 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8546380B2 (en) 2005-10-25 2013-10-01 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
EP2612854A1 (en) 2005-10-25 2013-07-10 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
EP2597087A1 (en) 2005-10-25 2013-05-29 Shionogi&Co., Ltd. Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
JP5383484B2 (en) * 2007-04-24 2014-01-08 塩野義製薬株式会社 Aminodihydrothiazine derivatives substituted with cyclic groups
RU2476430C2 (en) * 2007-04-24 2013-02-27 Сионоги Энд Ко., Лтд. Aminodihydrothiazine derivatives substituted by cyclic group
US8168630B2 (en) 2007-04-24 2012-05-01 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
WO2008133273A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Pharmaceutical composition for treatment of alzheimer's disease
US8541408B2 (en) 2007-04-24 2013-09-24 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8884062B2 (en) 2007-04-24 2014-11-11 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
JP2013216666A (en) * 2007-04-24 2013-10-24 Shionogi & Co Ltd Aminodihydrothiazine derivative substituted with cyclic group
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
EP2689780A1 (en) 2007-04-24 2014-01-29 Shionogi & Co., Ltd. Intermediates for aminodihydrothiazine derivatives substituted with a cyclic group
WO2008133274A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
US8895548B2 (en) 2007-04-24 2014-11-25 Shionogi & Co., Ltd. Pharmaceutical composition for treating alzheimer's disease
TWI423970B (en) * 2008-01-18 2014-01-21 Eisai R&D Man Co Ltd Fused aminodihydrothiazine derivatives
US8946210B2 (en) 2008-01-18 2015-02-03 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
US8946211B2 (en) 2008-01-18 2015-02-03 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
US7648983B2 (en) 2008-05-02 2010-01-19 Eli Lilly And Company BACE inhibitors
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
WO2009151098A1 (en) 2008-06-13 2009-12-17 塩野義製薬株式会社 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING β-SECRETASE-INHIBITING ACTIVITY
US9273053B2 (en) 2008-06-13 2016-03-01 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity
US9650371B2 (en) 2008-06-13 2017-05-16 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
WO2010041964A1 (en) * 2008-10-09 2010-04-15 Victoria Link Limited Methods for the preparation of alkenylamines, cyclic carbamates or dithiocarbamates, and aminoalcohols or aminothiols
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
US9290466B2 (en) 2009-12-11 2016-03-22 Shionogi & Co., Ltd. Oxazine derivatives
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US9656974B2 (en) 2009-12-11 2017-05-23 Shionogi & Co., Ltd. Oxazine derivatives
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US9758513B2 (en) 2012-10-24 2017-09-12 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
JP2016503785A (en) * 2012-12-19 2016-02-08 ファイザー・インク Carbocyclic and heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds
JP2016507551A (en) * 2013-02-13 2016-03-10 ファイザー・インク Heteroaryl-substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds
JP2016507580A (en) * 2013-02-15 2016-03-10 ファイザー・インク Substituted phenylhexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds
WO2019177142A1 (en) * 2018-03-16 2019-09-19 脳科学香料株式会社 Prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation, cell protection agent for transplantation, and bio-preservation agent
CN111918649A (en) * 2018-03-16 2020-11-10 脑科学香料株式会社 Prophylactic or therapeutic agent for hypoxia disorder, ischemia-reperfusion disorder or inflammation, cytoprotective agent for transplantation, and biological preservative
JPWO2019177142A1 (en) * 2018-03-16 2021-07-08 脳科学香料株式会社 Prophylactic or therapeutic agents for hypoxia, ischemia-reperfusion injury or inflammation, cytoprotectants for transplantation, and biopreservatives
US11590141B2 (en) 2018-03-16 2023-02-28 Scent Science International Inc. Prophylactic or therapeutic agent for hypoxic injury, ischemia-reperfusion injury and inflammation, cell protection agent for transplantation, and bio-preservation agent
CN111918649B (en) * 2018-03-16 2024-07-30 脑科学香料株式会社 Preventive or therapeutic agent for hypoxia, ischemia-reperfusion disorder or inflammation, cell protectant for transplantation, and biological preservative
US12076325B2 (en) 2018-03-16 2024-09-03 Scent Science International Inc. Prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation, cell protection agent for transplantation, and bio-preservation agent

Also Published As

Publication number Publication date
AU4149696A (en) 1996-06-06

Similar Documents

Publication Publication Date Title
WO1996014842A1 (en) Substituted heterocycles as inhibitors of nitric oxide synthase
US5629322A (en) Cyclic amidine analogs as inhibitors of nitric oxide synthase
US6372733B1 (en) Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases
EP0054951B1 (en) Dibenz(b,f)(1,4)oxazepine derivatives, process for preparing the same, and pharmaceutical compositions comprising the same
AU700078B2 (en) Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
WO1996018617A1 (en) Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
CA2224411A1 (en) Novel farnesyl transferase inhibitors, preparation thereof and pharmaceutical compositions containing said inhibitors
CA2654540A1 (en) Histone deacetylase and tubulin deacetylase inhibitors
MX2014004503A (en) Substituted biaryl alkyl amides.
EP2024335B1 (en) Novel imidazole derivatives, preparation and user thereof as medicine
US5173486A (en) Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents
US6114537A (en) Process for scavenging thiols
FR2944524A1 (en) IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT
CZ20011551A3 (en) Benzoyl pyridazine derivative, process of its preparation and pharmaceutical preparation in which it is comprised
US5821261A (en) Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase
EP0147317A2 (en) Ortho-condensed pyrrole derivatives, their preparation and medicaments containing them
JPWO2004111024A1 (en) Thiadiazoline derivatives
GB2217709A (en) Anti-tumour 4-oxoquinazolines
DE69221634T2 (en) 5-piperazinylalkyl) -1,5-benzothiazepinone usable as calcium antagonists
FR2539417A1 (en) NEW PYRROLO-1, 2 HETEROCYCLES, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM
EP0529395A2 (en) Benzamide multidrug resistance reversing agents
AU598285B2 (en) Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and pharmaceutical compounds comprising the same
US5908842A (en) Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
Mashelkar et al. Synthesis of some novel 4-substituted coumarins having potential biological activity (Part III)
CN116217553B (en) A triazone compound and its preparation method and application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 817130

Date of ref document: 19970407

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase